WO1989005859A1 - Agrobacterium mediated transformation of germinating plant seeds - Google Patents
Agrobacterium mediated transformation of germinating plant seeds Download PDFInfo
- Publication number
- WO1989005859A1 WO1989005859A1 PCT/US1988/004464 US8804464W WO8905859A1 WO 1989005859 A1 WO1989005859 A1 WO 1989005859A1 US 8804464 W US8804464 W US 8804464W WO 8905859 A1 WO8905859 A1 WO 8905859A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plant
- gene
- plants
- agrobacterium
- transfer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8202—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by biological means, e.g. cell mediated or natural vector
- C12N15/8205—Agrobacterium mediated transformation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
Definitions
- This invention relates to a process for transforming the germinating seed of a plant and the use of said process to produce transformed plants, particularly dicotyledonous plants.
- tissue culture procedures have not been established for many crop species. In most cases, gene transfers into crop species have been limited to transformed callus, not whole crop plants. In addition, tissue culture procedures can result in rearrangement of the inserted DNA; or somatic mutations may occur and result in the loss or alteration of desirable genetic traits accumulated by the expertise of many years of plant breeding.
- Agrobacterium-mediated gene transfers are by far the most widely used gene transfer techniques, but the use of Agrobacterium strains may be limited because they do not efficiently infect monocotyledonous cereal crop species.
- recent reports (Hooykaas-Van Slogteren et al., 1984; Hernalsteens et al., 1984; Graves and Goldman, 1986; Grimsley et al., 1987; Schafer et al., 1987; Bytebier et al., 1987) suggest that conditions exist whereby Agrobacterium strains can bind to monocotyledonous plant cells and transfer their T-DNA regions into these cells.
- leguminous plants The development of gene transfer techniques for leguminous plants is of commercial interest because it facilitates the development of new cultivars with improved disease resistance, tolerance to specific herbicides and increased nutritional value.
- these dicotyledonous species are susceptible to Agrobacterium infections (Facciotti et al., 1985; Owens and Cress, 1985; Byrne et al., 1987)
- its use for transformation is limited due to the lack of available and efficient regeneration procedures, especially for transformed tissues.
- Extension of this technique to germinating seed of leguminous plants such as Phaseolus vulgaris., the common bean is of great importance because regeneration procedures are not available, let alone the regeneration of transformed undifferentiated tissues.
- the process of this invention represents (1) an improvement of the Graves and Goldman (1986) technique for the transformation of the seeds of monocotyledous plants and (2) its extension to dicotyledonous plants.
- a process for producing a transgenic plant which comprises:
- inoculations with virulent Agrobacterium strain A208 were done at various times after initiating germination, between 6 to 96 hours. Successful transformation was scored by gall formation on the developing seedlings, the results of inoculating 50 seeds for each time interval is presented in Table I. Seeds allowed to germinate between 24 to 48 hours were found to be the most susceptible to Agrobacterium infections. Between 70% to 80% of these inoculated seeds gave rise to seedlings with galls formed either on the hypocotyl, epicotyl, cotyledonary node, or distributed throughout the base of the plant.
- a preferred method of inoculation is with a virulent or non-virulent Agrobacterium strain containing a transferable DNA cis or trans plasmid
- a particularly preferred manner of practicing the process on dicots involves removing one of the cotyledons prior to inoculation. This step increases access of the strain to the mesocotyl region wherein the meristematic cells are generated.
- the method of this invention is simple, rapid, avoids the use of any tissue culture techniques, and transformed plants can be obtained directly. Also provided are:
- Transgenic plants prepared by the process of this invention Preferred are dicotyledonous transgenic plants. Especially preferred are dicotyldonous plants of the family leguminoseae. such as phaseolus vulgaris and Glycinus max. DESCRIPTION OF THE PREFERRED EMBODIMENT
- Germinating seeds are inoculated with either virulent or non- virulent Agrobacterium tumefacien or Agrobacterium rhizogenes strains which contain the binary plasmid pGA472 or PGA482 or their deriv atives. Both are available from Dr. G. An, Washington State University, Pullman, WA. This binary plasmid encodes a plant expressible NPT II gene within its T-DNA region and their derivatives contain genes that will convey useful traits to transformed species. Most plants resulting from seeds inoculated with virulent Agrobacterium strains, which also contained the binary plasmid, developed typical crown galls.
- NPT II activity was found in the leaves of some inoculated whole plants, indicating that the binary T-DNA region was also transferred. Transfer of the binary T-DNA region was also accomplished by using avirulent strains of A. tumefaciens or rhizogenes. Results presented here show that 1.6% of the P . vulgaris and about 1% of the Glycine Max (soybean) plants were transformed, with transformation being determined by the presence of NPT II enzyme activity. Seeds of Phaseolus vulgaris cv.
- Olathe or Glvcine max (cV.A0949) were surface sterilized with 15% Clorox for 10 minutes, followed by 4-5 rinses with distilled water and then placed on moistened paper towels in a temperature controlled Percival incubator at 28oC. and allowed to germinate for various times, 16 to 96 hours. Seed coats were removed and the decoated seeds were opened in halves (that is how cotyledons were removed from the main seed body). The mesocotyl region of the germinating seeds, with their plummule still attached, were infected with an overnight liquid culture of various Agrobacterium strains by using an Eppendorf pipetter fitted with a 27 1/2 gauge needle. Seeds were infected with virulent or avirulent A.
- tumefaciens strains (A208, C58, C58z707 and A208/phas-zein) or A. rhizogenes strains [A4RS and A4RS(pR:B278b)pu3.3c-1].
- the common A. tumefaciens and A. rhizogenes strains are available from ATCC, 12301 Parklawn Drive, Rockville, MD.
- the disarmed A. rhizogenes strain RS(pRiB278b) has been described by Vilaine and Casse-Delbart (1987) Mol. Gen. Genet., 206,17 and is available from Dr. F.
- NPT II enzyme activity was detected by the in situ gel assay as reported by Reiss et al. (1984). Briefly, 100 mg. of a leaf tissue was mixed with 20 ml . of extraction buffer in a 1.5 ml. Eppendorf tube. Tissue samples were macerated with a Konte pestle and centrifuged for 20 minutes at 4°C. A 35 ⁇ l aliquot of the supernatant solutions was electrophoresed on a non-denaturing 10% polyacrylamide gel. The gel was overlaid with a 1% agarose gel containing 67 mM. tris-maleate (pH 7.1), 42 mM. MgCl 2 .
- Example 1 The purpose of these examples is to show that gene constructions exist, either constructed by us or others, which when transferred, integrated, and expressed in a plant will convey a useful trait to that plant.
- Example 1 The purpose of these examples is to show that gene constructions exist, either constructed by us or others, which when transferred, integrated, and expressed in a plant will convey a useful trait to that plant.
- Example 1 The purpose of these examples is to show that gene constructions exist, either constructed by us or others, which when transferred, integrated, and expressed in a plant will convey a useful trait to that plant.
- Germinating P. vulgaris and G. max seeds were inoculated about 24 hours after germination with virulent and avirulent Agrobacterium strains which contained modified pGA482G [constructed by clearing the SalF fragment from pWP866 which contains the gene for gentamycin-(3)- N-acetyl-benferose III, and is available from W. Piepersberg, P-8080, Kunststoff, Federal Republic of Germany, into one of the SaIl sites in pGA482, based binary vector constructions pPhas-zein [which contains the corn beta-zein gene (Pedersen et al., 1987 and is available from Dr. B. Larkins, Purdue University, West Lafayette, IN) transcriptionally linked to the P.
- modified pGA482G constructed by clearing the SalF fragment from pWP866 which contains the gene for gentamycin-(3)- N-acetyl-benferose III, and is available from W. Piepersberg, P-8080, Kunststoff, Federal Republic
- Transfer and expression of the plant expressible NPT II gene contained within the T-DNA region of pGA482G was determined by removing two to three young leaves (usually obtained 10 inches or more above the wound site resulting from inoculating the germinating seeds), extracting the soluble proteins and testing for NPT II activity. From a total of 695 plants tested only 11 plants showed NPT II activity in these protein extracts. They are listed in Table II and the NPT II positive results are shown in Chart 2. About 1.6% of the surviving inoculated seeds show NPT II activity, suggesting that the T-DNA region of the binary plasmid pGA482G is integrated in the genome of these P. vulgaris plants.
- microinjection and high-velocity microprojectiles can be used to transfer DNAs into the mesocotyl region and that transformed plants should result.
- phaseolin Using the P. vulgaris seed storage protein gene, phaseolin, and its cDNA counterpart a mutant phaseolin gene lacking its five introns was constructed.
- This mutant phaseolin gene (phas-minigene) retains it natural 5' and 3' plant-regulatory sequences and the construction of this plasmid (pPv3.3-cDNA) has been described by Chee et al. (1986) Gene 41:47 and Cramer et al. (1985) Proc. Natl. Acad. Sci. 82; 334 and is available from Agrigenetics Corp. Madison, WI.
- Plasmid pPv3.3-cDNA was subjected to restriction enzyme digests, BamHI and HindIII and a 3.6 kb fragment was removed and cloned into BglII and HindIII sites of the binary vector pGA482 (An et al. (1985) EMBO. J. 4:277).
- This construction places this mutant phaseolin gene within the right and left borders of the binary plasmid, now referred to as p/i3.3c-l, and along side of the plant expressible NPT II gene which is used for selection and identification of transformed plants.
- the structure of binary plasmid pu3.3c-l is shown in Chart 1. 2.2 Use of pu3.3c-l
- This binary plasmid has to be transferred into various Agrobacterium strains, i.e. A208, C58, C58:707, LBA4404 and A4RS, etc.
- the method described here can be used to transfer the binary plasmid p ⁇ 3.3c-l into various plant species (e.g., common bean, soybean and other large seeded plants).
- multiple copies of the phaseolin minigene can be placed into the binary plasmid by subcloning the NcoI to BamHI fragment (3 kb fragment) frompPv3.3-CDNA into NcoInd BamHI digested clone pPr 8.8 g (available from J.
- the orientation of the new phaseolin insert(s) can be checked and only those in the 5' and 3' orientation with respect to the first phaseolin gene are used, for additional insertions. Because only the 3' BamHI site was retained (the BglII/BamHI ligated site is not digestible by either enzyme) this step could be repeated any number of times, depending on plasmid stability and ability to still transform E.coli and Agrobacteria. This procedure was repeated to obtain as many as four phaseolin gene inserts, which were cloned using a Hindlll and BamHI digest into the binary plasmid pGA482G. Having a series of these plasmids with different numbers of phaseolin genes (this can also be referred to as gene family transfer since a family of similar genes is transferred in a single event) will increase the level of storage proteins in seeds of transformed plants.
- the purpose of this example is to incorporate a modified seed storage protein which encodes a higher percentage of sulfur-containing amino acids; such a gene is referred to as High Sulfur Storage
- HSSP Protein
- This gene is constructed so that it is developmentally expressed in the seeds of dicotyledonous plants; this has been accomplished by using the phaseolin promoter.
- the modified gene must encode a substantial number of sulfur-containing amino acids.
- Naturally occurring HSSP-genes can also be used.
- the two best naturally occurring HSSP-genes are the beta zein gene (15 kD) (Pedersen et al (1986) J. Biol. Chem. 201:6279) and the Brazil nut protein
- any other natural or synthetic gene derivative of an HSSP-gene can be used for the improvement of the nutritional value of seeds.
- the construction of the zein derivative HSSP-gene uses the phaseolin gene promoter from clone pPv8.8-Bg [constructed by doing sight specific modification of pPv8.8g.
- the BglII to Xbal fragment for pPV8.8g was cloned into M13mp 17 (commercially available) to obtain clone as 13mpl8PVl.6. This was then used to produce single- stranded DNA which was annealed to an oligomer (30 residues) which contained a two-base pair change from the original phaseolin promoter region.
- the sequence of the oligomer was 5'CATCATAGTAGATCTAGTATTGAATATGAG-3' (opposite to coding strain).
- the modified clone ml3 mpl81.6 30.12.3 was isolated and DNA was isolated. From the isolated DNA an Ncol to Xbal fragment was removed and cloned into Ncol and the partial XbaI digested p 8.8g.
- the new clone containing the phaseolin promoter on a 800 bp Bgl II to Bgl II fragment was designated p Pv8.8g Bg.] to ensure proper expression and at a level expected for a seed storage protein, and the beta-zein clone pZGlSRX (Pedersen et al., ibid).
- phaseolin promoter was made accessible by a site specific mutation at position -7 which resulted in a Bglll site, thus the phaseolin promoter could be removed after a Bglll digest as an 800 bp fragment. This fragment was subcloned into the BamHI site of pUC18 (available from commercial sources), yielding a plasmid designate pUC-Pvpro.
- the beta-zein structural gene, including signal peptide, coding region, and Poly (A) addition signal was removed from plasmid pZG15EX (available from B.
- This new binary plasmid is referred to as pGA482G-Phas-zein (see Chart 2) and it was transferred into Agrobacterium strains: A208, C58, LBA4404, C58Z707, and A4RS which in turn can be used to produce transformed plants in accordance with the method of this invention.
- a phase zein construction similar to that described above has been transferred into dicotyledonous plants and its developmental expression in the seeds of the transformed plant has been observed; see Hoffman et al. (1987) EMBO J. 6:3213. Additional modification has been made to a Phas-zein gene construction.
- the purpose of this example is to generate a construction for the expression of a plant virus coat protein gene which, when expressed in a dicotyledonous plant, results in reduced symptoms or resistance to later infections by that virus (see report by Powell-Abel et al. (1986) Science 232:738).
- Viral coat proteins are isolated from any number of plant virus classes (tobamo, cucumo, poty, tobra, AMV, etc.) and they are expressed constitutively in plants after the attachment of the CaMV 35S promoter.
- a plant poly (A) signal is added to the 3' region to ensure proper expression.
- a clone containing any specific viral coat protein gene can be obtained for both plant DNA and RNA viruses.
- This poly (A) region was used to anneal an aligo dT primer which was used to prime the synthesis of single-stranded (SS) cDNA using reverse transriptos and appropriate buffer of CMV-C SS-cDNA, double-stranded cDNA was synthesized by adding RNaso H to remove the RNA from the duplex and the second strand was made by adding E. coli DNP polymerase I (Klenow fragment) and the appropriate buffer. After synthesis of CMA-C ds-DNA, it was E. coli methylated using Eco RI methylase and Eco methylent buffer, thus protecting all internal Eco RI sites in the CMV-C ds-cDNA molecules.
- the CMV-C ds-cDNA molecules were treated again with E coli polymorse I (Klenow fragment) to ensure that all ends (5' and 3') were flush, then these molecules were ligated to Eco RI linkers using T4-Ligase. After ligation the CMV-C ds-cDNA molecules were separated from contaminating linker by size fractionation on a GYOG column (1cm X 30cm). The fraction containing the majority of the CMV-C ds-cDNA molecules was EtOH precipitated, followed by resuspension in 10 ⁇ g of H20.
- CiMV constitutive cauliflower mosaic virus
- Attachment of the constitutive cauliflower mosaic virus (CaMV) 35S promoter was done by first doing a partial AccI and complete EcoRI digests of clone pCMV9.9 which was obtained by cloning the Eco RI insert from Lambda GT11-CMV9.9 into EcoRI cut puc 19 (commercially available). The 1100 bp CMV-C coat protein gene fragment was removed, both ends were blunted, and this fragment was cloned into the jjmal site of pDH51 (Pietrzak et al. (1986). fiuc. Acids Res. 14:5857) which is available from A.T.
- this plant expressible CMV-C coat protein gene was removed from clone pDH51/CP19 by an EcoRI digest and the 1800 bp fragment was cloned into pUCl813 (which contains more restriction enzyme sites and is available from Dr. R. Kay, Washington State University, Pullman, Washington. The resulting clone, pUCl813/CP19, was then partially digested with Hindlll and the 1800 bp fragment was cloned into the binary vector pGA482 to obtain the new clone, pGA482/CPl9H (see Chart 3).
- This binary plasmid, or its derivatives can be transferred into Agrobacterium strains: A208, C58, LBA4404, C58Z707, A4RS, A4RS(pRiB28b) and others.
- this plant expressible CMV-C coat protein gene (or any other plant virus coat protein gene) can be transferred into a dicotyledonous plant species such as, cucumber, squash, melon, zucchini, pepper, etc.
- the development of these new cultivars are useful because of their resistance to infections by specific virus or viruses (if more than one virus coat protein gene construction is transferred to a single plant).
- the purpose of this example is to illustrate how to generate plant expressible genes which allow a plant to be resistant to specific classes of herbicides. Such plants are useful for many reasons; (i) herbicides normally lethal can be used, and (ii) different crops can be used in close rotations on soil which may contain residual amounts of a previously used herbicide that is normally lethal to the second crop.
- Two genes of interest are mutant derivatives (derived from plant or bacterial sources) of the aceto ⁇ lactate synthase (ALS) gene which are not sensistive to chlorsulfuron and sulfometuron methyl herbicides (Falco et al., (1985) Biotech. Plant Sci. Academic Press, Inc.
- EPSPS enolpyruvylshikimate-3-phosphate synthase
- a gene which encodes an important enzyme which is either resistant to or detoxifies a specific herbicide is cloned downstream from a plant active promoter, such as: CaMV 35S, ribulose-1,5-bisphosphate carboxylase small subunit gene, or other strong plant gene promoter and upstream from a plant gene poly (A) signal sequence, see Chart 4.
- This gene is then be cloned into an Agrobacterium-derived vector (either binary or cis) and using the above-described plant transformation method, such a gene is be transferred into many dicotyledonous plant species, such as: soybean, common bean, peppers, melons, etc.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Botany (AREA)
- Environmental Sciences (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A non-tissue culture process using Agrobacterium-mediated vectors to produce transgenic plants from seeds of such plants as the common bean and soybean.
Description
AGROBACTERIUM MEDIATED TRANSFORMATION OF GERMINATING PLANT SEEDS FIELD OF INVENTION This invention relates to a process for transforming the germinating seed of a plant and the use of said process to produce transformed plants, particularly dicotyledonous plants.
BACKGROUND OF THE INVENTION The development of single gene transfer techniques for plant species is of great interest and value to plant breeders because it can be used for the rapid transfer of beneficial genetic traits to plants. Numerous methods have been developed for transferring genes into plant tissues; Agrobacterium-mediated transfer (Murai et al.. 1983; Fraley et al., 1983), direct DNA uptake (Paszkowski et al., 1984; Potrykus et al., 1985), microinjection (Crossway et al., 1986), high-velocity microprojectiles (Klein et al., 1987) and electroporation (Fromm et al., 1985; Fromm et al., 1986). A general problem with most of these gene transfer techniques is that the transformed tissues, either leaf pieces or cellular protoplast, must be subjected to some regeneration steps which require a considerable amount of time before a whole plant can be obtained. This process is further complicated because tissue culture procedures have not been established for many crop species. In most cases, gene transfers into crop species have been limited to transformed callus, not whole crop plants. In addition, tissue culture procedures can result in rearrangement of the inserted DNA; or somatic mutations may occur and result in the loss or alteration of desirable genetic traits accumulated by the expertise of many years of plant breeding.
Agrobacterium-mediated gene transfers are by far the most widely used gene transfer techniques, but the use of Agrobacterium strains may be limited because they do not efficiently infect monocotyledonous cereal crop species. However, recent reports (Hooykaas-Van Slogteren et al., 1984; Hernalsteens et al., 1984; Graves and Goldman, 1986; Grimsley et al., 1987; Schafer et al., 1987; Bytebier et al., 1987) suggest that conditions exist whereby Agrobacterium strains can bind to monocotyledonous plant cells and transfer their T-DNA regions into these cells. Interestingly, the report by Graves and Goldman (1986) suggests that Agrobacteria can infect scutellar and mesocotyl cells of germinating corn (Zea mays) seeds and that the
resulting plants are transformed, although these transformed plants will be sectored. This technique suggests, that Agrobacterium-mediated gene transfer can be accomplished without the need of any tissue culture intermediate steps. Additional support for the transformation of mesocotyl cells of germinating seeds was obtained by Feldmann and Marks (1987) as they were able to obtain G418 resistant Arabidopsis thaliana plants by co-cultivating germinating seeds with Agrobacteria containing a binary plasmid with a plant expressible neomycin phosphotransferase (NPT) II gene in its T-DNA region.
The development of gene transfer techniques for leguminous plants is of commercial interest because it facilitates the development of new cultivars with improved disease resistance, tolerance to specific herbicides and increased nutritional value. Unfortunately, even though these dicotyledonous species are susceptible to Agrobacterium infections (Facciotti et al., 1985; Owens and Cress, 1985; Byrne et al., 1987), its use for transformation is limited due to the lack of available and efficient regeneration procedures, especially for transformed tissues. Extension of this technique to germinating seed of leguminous plants such as Phaseolus vulgaris., the common bean, is of great importance because regeneration procedures are not available, let alone the regeneration of transformed undifferentiated tissues.
The development of simple, non-tissue culture dependent methods for transfer, stable integration, and sexual transmission of genetic material into plant species is of great interest and importance. Reports from Graves and Goldman (1986) and Feldmann and Marks (1987) present evidence that transformed whole plants can be obtained via Agrobacterium-mediated transformation of the mesocotyl cells of germinating seeds.
The process of this invention represents (1) an improvement of the Graves and Goldman (1986) technique for the transformation of the seeds of monocotyledous plants and (2) its extension to dicotyledonous plants. INFORMATION DISCLOSURE
An G, Watson et al., (1985) New cloning vehicles for transformation of higher plants. EMBO J. 4:277-284.
Byrne M.C. et al., (1987) Strain and cultivar specificity in the
Agrobacterium- soybean interaction. Plant Cell Tissue and Organ Culture 8: 3-15.
Bytebier B. et al., (1987) T-DNA organization in tumor cultures and transgenic plants of the monocotyledon Asparagus officinalis. Proc. Natl. Acad. Sci. USA 84: 5345-5349.
Chee P. P. et al., (1986) Expression of a bean storage protein "phaseolin minigene" in foreign plant tissues. Gene 41: 47-57.
Crossway A. et al., (1986) Integration of foreign DNA following microinjection of tobacco mesophyll protoplasts. Mol Gen Genet 202:179-185.
Facciotti D. et al., 1985) Light-indueible expression of a chimeric gene in soybean tissue transformed with Agrobacterium Biotechnology 3:241-246.
Feldmann K. A. et al., (1987) Agrobacterium-mediated transfor- mation of germinating seeds of Arabidopsis thaliana: A non-tissue culture approach. Mol Gen Gent 208:1-9.
Fraley R. T. et al., (1983) Expression of bacterial genes in plant cells. Proc Natl Acad Sci USA 80:4803-4807.
Fromm M. E. et al., (1986) Stable transformation of maize after gene transfer by electroporation. Nature 319:791-793.
Fromm M, et al., (1985) Expression of genes transferred into monocot and dicot plant cells by electroporation. Proc Natl Acad Sci USA 82:5824-5828.
Graves A. C. F. et al., (1986) The transformation of Zea mays seedlings with Agrobacterium tumefaciens. Plant Mol Biol 7:43-50.
Grimsley N. et al., (1987) Agrobacterium-mediated delivery of infectious maize streak virus into maize plants. Nature 325:177-179.
Hooykaas-Van Slogteren G.M.S. et al., (1984) Expression of Ti plasmid genes in monocotyledonous plants infected with Agrobacterium tumefaciens. Nature 311:763-764.
Hernalsteens J.P., et al, (1984) An Agrobacterium-transformed cell culture from the monocot Asparagus officinalis. EMBO J 3:3039-3044.
Jefferson (1986) B-Glucuronolose from Escherichia coli as a gene fusion marker. Proc. Natl. Acad. Sci., USA 83:8447-8451.
Klein T.M. et al.; (1987). High-velocity microprojectiles for delivering nucleic acids into living cells. Nature 327:70-73.
Murai N. et al., (1983) Phaseolin Gene from Bean is Expressed
after transfer to Sunflower via Tumor-inducing Plasmid Vectors. Science 222:476-482.
Owens L.D. et al., (1985) Genotypic variability of soybean response to Agrobacterium strains harboring the Ti or Ri plasmids. Plant Physiol 77:87-94.
Paszkowski J. et al., (1984) Direct gene transfer to plants. EMBO J 3:2717-2722.
Pedersen K. et al., (1986) Sequence analysis and characterization of a maize gene encoding a high-sulfur zein protein of MW 15,000. J. Biol Chem 261:6279-6284.
Potrykus I. et al., (1985) Direct gene transfer to cells of a graminaceous monocot. Mol Gen Genet 199:183-188.
Reiss B. et al., (1984). A new sensitive method for qualitative and quantitative assay of neomycin phosphotransferase in crude cell extracts. Gene 30:211-218.
Schafer W. et al., (1987). T-DNA integration and expression in a monocot crop plant after induction of Agrobacterium. Nature 328:539-532.
Slightom J.L. et al,, (1983). Complete nucleotide sequence of a French bean storage protein gene. Phaseolin. Proc Natl Acad Sci USA 80:1897-1901.
A non-tissue culture approach for preparing transformed arabidopsis thaliana seeds is described by Feldmann and Marks, Mol. Gen. Genet. (1987) 208:19. However, to the inventors' knowledge the application of non-tissue culture transfer has not been successfully applied to leguminous plants and other large seed dicots such as soybean, the common bean, squash, zucchini, peppers, and others.
SUMMARY OF THE INVENTION The present invention provides : A process for producing a transgenic plant which comprises:
(a) germinating a seed of a plant;
(b) inoculating the meristematic or mesocotyl cells produced during germination, prior to their differentiation, with a virulent or non-virulent Agrobacterium strain containing a transferable gene in an Agrobacterium derived vector; and
(c) allowing the cells to differentiate into mature plants, with the proviso that the plant cannot be from the family Arabidopsis thaliana.
The time of infecting germinating P. vulgaris seed after germination with the Agrobacterium-based vectors- has been found to be critical. The length of time the seeds are allowed tc germinate prior to Agrobacteria infection will greatly affect the ability of the Agrobacteria to infect meristematic cells, because the amount of vascular tissue is rapidly increasing as differentiation proceeds. However, seed germination must take place in order to have physical access to the mesocotyl region. Therefore a preferred manner of practicing the invention is to conduct the inoculation step within 16 to 96, preferably 24 to 48, hours of germination. To determine the optimum time for infecting germinating seeds, inoculations with virulent Agrobacterium strain A208 , were done at various times after initiating germination, between 6 to 96 hours. Successful transformation was scored by gall formation on the developing seedlings, the results of inoculating 50 seeds for each time interval is presented in Table I. Seeds allowed to germinate between 24 to 48 hours were found to be the most susceptible to Agrobacterium infections. Between 70% to 80% of these inoculated seeds gave rise to seedlings with galls formed either on the hypocotyl, epicotyl, cotyledonary node, or distributed throughout the base of the plant. A preferred method of inoculation is with a virulent or non-virulent Agrobacterium strain containing a transferable DNA cis or trans plasmid
A particularly preferred manner of practicing the process on dicots involves removing one of the cotyledons prior to inoculation. This step increases access of the strain to the mesocotyl region wherein the meristematic cells are generated.
The method of this invention is simple, rapid, avoids the use of any tissue culture techniques, and transformed plants can be obtained directly. Also provided are:
Transgenic plants prepared by the process of this invention. Preferred are dicotyledonous transgenic plants. Especially preferred are dicotyldonous plants of the family leguminoseae. such as phaseolus vulgaris and Glycinus max. DESCRIPTION OF THE PREFERRED EMBODIMENT
Germinating seeds are inoculated with either virulent or non- virulent Agrobacterium tumefacien or Agrobacterium rhizogenes strains which contain the binary plasmid pGA472 or PGA482 or their deriv
atives. Both are available from Dr. G. An, Washington State University, Pullman, WA. This binary plasmid encodes a plant expressible NPT II gene within its T-DNA region and their derivatives contain genes that will convey useful traits to transformed species. Most plants resulting from seeds inoculated with virulent Agrobacterium strains, which also contained the binary plasmid, developed typical crown galls. However, NPT II activity was found in the leaves of some inoculated whole plants, indicating that the binary T-DNA region was also transferred. Transfer of the binary T-DNA region was also accomplished by using avirulent strains of A. tumefaciens or rhizogenes. Results presented here show that 1.6% of the P . vulgaris and about 1% of the Glycine Max (soybean) plants were transformed, with transformation being determined by the presence of NPT II enzyme activity. Seeds of Phaseolus vulgaris cv. Olathe or Glvcine max (cV.A0949) were surface sterilized with 15% Clorox for 10 minutes, followed by 4-5 rinses with distilled water and then placed on moistened paper towels in a temperature controlled Percival incubator at 28ºC. and allowed to germinate for various times, 16 to 96 hours. Seed coats were removed and the decoated seeds were opened in halves (that is how cotyledons were removed from the main seed body). The mesocotyl region of the germinating seeds, with their plummule still attached, were infected with an overnight liquid culture of various Agrobacterium strains by using an Eppendorf pipetter fitted with a 27 1/2 gauge needle. Seeds were infected with virulent or avirulent A. tumefaciens strains (A208, C58, C58z707 and A208/phas-zein) or A. rhizogenes strains [A4RS and A4RS(pR:B278b)pu3.3c-1]. The common A. tumefaciens and A. rhizogenes strains are available from ATCC, 12301 Parklawn Drive, Rockville, MD. The disarmed A. rhizogenes strain RS(pRiB278b) has been described by Vilaine and Casse-Delbart (1987) Mol. Gen. Genet., 206,17 and is available from Dr. F. Casse-Delbart, C.N.R.A., Routede Saint Cyr, F78000, Versailles, France. The disarmed A. tumefaciens. strain C582707 is available from Dr. A. G. Hepburn, University of Illinois, Urbana, IL. Inoculated seeds were then placed on moistened paper towels in petri dishes and incubated at 28"C. After four days these seedlings were transformed to soil and grown to maturity in the greenhouse. Plants infected with virulent strains of A. tumefaciens were scored for efficiency of gall
formation as a function of germination time. NPT II Enzvme Activity
NPT II enzyme activity was detected by the in situ gel assay as reported by Reiss et al. (1984). Briefly, 100 mg. of a leaf tissue was mixed with 20 ml . of extraction buffer in a 1.5 ml. Eppendorf tube. Tissue samples were macerated with a Konte pestle and centrifuged for 20 minutes at 4°C. A 35 μl aliquot of the supernatant solutions was electrophoresed on a non-denaturing 10% polyacrylamide gel. The gel was overlaid with a 1% agarose gel containing 67 mM. tris-maleate (pH 7.1), 42 mM. MgCl2. 400 mM NH4CI, 20 μg kanamycin sulfate and 200 μCi gamma- [32p]ATP. After incubating for 30 minutes at room temperature, the agarose gel was blotted onto Whatman P81 phosphocellulose paper overnight. The P81 paper was removed, washed several times with hot water (80°C.) and autoradiographed. The following examples utilize many techniques well known and accessible to those skilled in the arts of molecular biology and manipulation of Agrobacterium strains and plasmids (virulent, avirulent, cis- or trans- configurations). Enzymes are obtained from commercial sources and are used according to the vendor's recommendations or other variations known to the art. Reagents, buffers and culture conditions are also known to those in the art. General references containing such standard techniques include the following: R. Wu, ed. (1979) Meth. Enzvmol. Vol. 68; J. H. Miller (1972) Experiments in Molecular Genetics: T. Maniatis et al. (1982) Molecular Cloning: A Laboratory Manual; and D. M. Glover, ed. (1985) DNA Cloning Vol. II, all of which are incorporated by reference.
The purpose of these examples is to show that gene constructions exist, either constructed by us or others, which when transferred, integrated, and expressed in a plant will convey a useful trait to that plant. Example 1.
Germinating P. vulgaris and G. max seeds were inoculated about 24 hours after germination with virulent and avirulent Agrobacterium strains which contained modified pGA482G [constructed by clearing the SalF fragment from pWP866 which contains the gene for gentamycin-(3)- N-acetyl-benferose III, and is available from W. Piepersberg, P-8080, Munich, Federal Republic of Germany, into one of the SaIl sites in pGA482, based binary vector constructions pPhas-zein [which contains
the corn beta-zein gene (Pedersen et al., 1987 and is available from Dr. B. Larkins, Purdue University, West Lafayette, IN) transcriptionally linked to the P. vulgaris seed storage protein gene promotor (Slightom et al., 1983) or pu3.3c-1 [which contains the phaseolin minigene construction (Chee et al., 1985) and is available from Agrigenetics Corp, Madison, WI]. Physical maps of these binary plasmids are presented in Chart 2.
Transfer and expression of the plant expressible NPT II gene contained within the T-DNA region of pGA482G (An et al., 1984) was determined by removing two to three young leaves (usually obtained 10 inches or more above the wound site resulting from inoculating the germinating seeds), extracting the soluble proteins and testing for NPT II activity. From a total of 695 plants tested only 11 plants showed NPT II activity in these protein extracts. They are listed in Table II and the NPT II positive results are shown in Chart 2. About 1.6% of the surviving inoculated seeds show NPT II activity, suggesting that the T-DNA region of the binary plasmid pGA482G is integrated in the genome of these P. vulgaris plants.
Other procedures, well known to those skilled in the art, such as microinjection and high-velocity microprojectiles, can be used to transfer DNAs into the mesocotyl region and that transformed plants should result.
TABLE I
Frequency of Gall Formation on Seedlings Inoculated
With the Agrobacterium Strain A208
Germination Periods Frequuncy of Gall Formation
6 hours 0
12 hours 0
24 hours 80
36 hours 70
48 hours 40
72 hours 10
90 hours 10
TABLE II
NPT II Positive Transformed Plants
Plant Number Binary Construction Gall
40 C58/phas-zein +
41 C58/phas-zein +
46 C58/phas-zein +
61 C58/phas-zein -
65 C58/phas-zein -
151 C58/phas-zein +
258 A4RS(pR:B278b)pu3.3c-1 -
269 A4RS(pR:B278b)pu3.3c-1 -
296 A4RS(PR:B278b)pu3.3c-1 -
470 A208/phas-zein -
552 C58Z707/phas-zein -
Example 2
Construction of a micro-Ti plasmid for the expression of a phaseolin mini-gene. The transfer and expression of this gene will increase the level of seed storage protein in the transformed plant. 2.1
Using the P. vulgaris seed storage protein gene, phaseolin, and its cDNA counterpart a mutant phaseolin gene lacking its five introns was constructed. This mutant phaseolin gene (phas-minigene) retains it natural 5' and 3' plant-regulatory sequences and the construction of this plasmid (pPv3.3-cDNA) has been described by Chee et al. (1986) Gene 41:47 and Cramer et al. (1985) Proc. Natl. Acad. Sci. 82; 334 and is available from Agrigenetics Corp. Madison, WI. Plasmid pPv3.3-cDNA was subjected to restriction enzyme digests, BamHI and HindIII and a 3.6 kb fragment was removed and cloned into BglII and HindIII sites of the binary vector pGA482 (An et al. (1985) EMBO. J. 4:277). This construction places this mutant phaseolin gene within the right and left borders of the binary plasmid, now referred to as p/i3.3c-l, and along side of the plant expressible NPT II gene which is used for selection and identification of transformed plants. The structure of binary plasmid pu3.3c-l is shown in Chart 1. 2.2 Use of pu3.3c-l
This binary plasmid has to be transferred into various Agrobacterium strains, i.e. A208, C58, C58:707, LBA4404 and A4RS, etc. The method described here can be used to transfer the binary plasmid pμ3.3c-l into various plant species (e.g., common bean, soybean and other large seeded plants). In addition, multiple copies of the phaseolin minigene can be placed into the binary plasmid by subcloning the NcoI to BamHI fragment (3 kb fragment) frompPv3.3-CDNA into NcoInd BamHI digested clone pPr 8.8 g (available from J. Slightom, The Upjohn Company, Kalamazoo, MI) which replaces the genomic part with the CDNA region of pPV3.3-cDNA. This cloning experiment results in obtaining subclone pPv8.3-cDNA which contains an upstream BglII site (Slightom, et al. (1983) Proc. Natl, Acad. Sci.. 80:1897) which allows for the isolation of a BglII-BamHI 3.3,5 kb fragment which was recloned into the BamHI digested plasmid pPv3.3-cDNA. The orientation of the new phaseolin insert(s) can be checked and only those in the 5' and 3' orientation with respect to the first phaseolin gene are used, for additional insertions. Because
only the 3' BamHI site was retained (the BglII/BamHI ligated site is not digestible by either enzyme) this step could be repeated any number of times, depending on plasmid stability and ability to still transform E.coli and Agrobacteria. This procedure was repeated to obtain as many as four phaseolin gene inserts, which were cloned using a Hindlll and BamHI digest into the binary plasmid pGA482G. Having a series of these plasmids with different numbers of phaseolin genes (this can also be referred to as gene family transfer since a family of similar genes is transferred in a single event) will increase the level of storage proteins in seeds of transformed plants. Example 3
The purpose of this example is to incorporate a modified seed storage protein which encodes a higher percentage of sulfur-containing amino acids; such a gene is referred to as High Sulfur Storage
Protein (HSSP)-gene. This gene is constructed so that it is developmentally expressed in the seeds of dicotyledonous plants; this has been accomplished by using the phaseolin promoter. The modified gene must encode a substantial number of sulfur-containing amino acids. Naturally occurring HSSP-genes can also be used. The two best naturally occurring HSSP-genes are the beta zein gene (15 kD) (Pedersen et al (1986) J. Biol. Chem. 201:6279) and the Brazil nut protein
(Altenbach et al. (1987) Plant Mol. Bio. 8:239). However, any other natural or synthetic gene derivative of an HSSP-gene can be used for the improvement of the nutritional value of seeds.
3.1 Construction of a HSSP-gene
The construction of the zein derivative HSSP-gene uses the phaseolin gene promoter from clone pPv8.8-Bg [constructed by doing sight specific modification of pPv8.8g. The BglII to Xbal fragment for pPV8.8g was cloned into M13mp 17 (commercially available) to obtain clone as 13mpl8PVl.6. This was then used to produce single- stranded DNA which was annealed to an oligomer (30 residues) which contained a two-base pair change from the original phaseolin promoter region. The sequence of the oligomer was 5'CATCATAGTAGATCTAGTATTGAATATGAG-3' (opposite to coding strain). After annealing DNA polymerase I (Klenow fragment) was added and the remaining opposite strand of M13MP18pvl.6 was synthesized. The mutant M13 clone, containing a new Bgl site 7 bp from the translation start site
(Slightom et al, 1983, ibid) of the phaseloin gene, was screened using the 32p-labeled oligomer and differential., temperature hybridization. Cloned candidates were further analyzed by doing Bgl II digestions and agarose gel electrophoresis to identify particular clones containing the extra Bgl II. site, the appearance of the Bgl II to Bgl II 800 bp fragment. The modified clone ml3 mpl81.6 30.12.3 was isolated and DNA was isolated. From the isolated DNA an Ncol to Xbal fragment was removed and cloned into Ncol and the partial XbaI digested p 8.8g. The new clone containing the phaseolin promoter on a 800 bp Bgl II to Bgl II fragment was designated p Pv8.8g Bg.] to ensure proper expression and at a level expected for a seed storage protein, and the beta-zein clone pZGlSRX (Pedersen et al., ibid). The phaseolin promoter was made accessible by a site specific mutation at position -7 which resulted in a Bglll site, thus the phaseolin promoter could be removed after a Bglll digest as an 800 bp fragment. This fragment was subcloned into the BamHI site of pUC18 (available from commercial sources), yielding a plasmid designate pUC-Pvpro. The beta-zein structural gene, including signal peptide, coding region, and Poly (A) addition signal was removed from plasmid pZG15EX (available from B. Larkins, Purdue University, West Lafayette, IN) after a TagI digestion and this fragment was cloned into the Accl site of pUC-Pvpro, yielding clone pUC-Phas-zein. This Phaszein gene was removed by digestion with Hindlll and EcoRI and this fragment was cloned into the binary vector pGA482G, which had previously been digested with HindIII and EcoRI. This new binary plasmid is referred to as pGA482G-Phas-zein (see Chart 2) and it was transferred into Agrobacterium strains: A208, C58, LBA4404, C58Z707, and A4RS which in turn can be used to produce transformed plants in accordance with the method of this invention. A phase zein construction similar to that described above has been transferred into dicotyledonous plants and its developmental expression in the seeds of the transformed plant has been observed; see Hoffman et al. (1987) EMBO J. 6:3213. Additional modification has been made to a Phas-zein gene construction. These modifications include the ligation of a BglII linker onto its 5' -end and a BamHI linker onto its 3'-end which allows the construction of multiple copies of the phase zein gene as described above for the phaseolin minigene. This allows for the transfer of a HSSP-gene multigene
family into a plant species by a single transformation event and the expression of higher levels of the HSSP-gene product. This leads to the development of dicotyledonous plant varieties which are nutritionally improved, such as common bean, soybean and other large seeded plants.
Example 4 Transfer of Viral Resistance
The purpose of this example is to generate a construction for the expression of a plant virus coat protein gene which, when expressed in a dicotyledonous plant, results in reduced symptoms or resistance to later infections by that virus (see report by Powell-Abel et al. (1986) Science 232:738). Viral coat proteins are isolated from any number of plant virus classes (tobamo, cucumo, poty, tobra, AMV, etc.) and they are expressed constitutively in plants after the attachment of the CaMV 35S promoter. In addition, a plant poly (A) signal is added to the 3' region to ensure proper expression.
A clone containing any specific viral coat protein gene can be obtained for both plant DNA and RNA viruses. Such is the case for cucumber mosaic virus strain C (CMV-C); its RNA genome was copied into double-stranded cDNA and the coat protein gene was isolated and characterized as follows. A residues were added to the 3' end of CMV-C total RaH, using E. coli polyadenylose. This poly (A) region was used to anneal an aligo dT primer which was used to prime the synthesis of single-stranded (SS) cDNA using reverse transriptos and appropriate buffer of CMV-C SS-cDNA, double-stranded cDNA was synthesized by adding RNaso H to remove the RNA from the duplex and the second strand was made by adding E. coli DNP polymerase I (Klenow fragment) and the appropriate buffer. After synthesis of CMA-C ds-DNA, it was E. coli methylated using Eco RI methylase and Eco methylent buffer, thus protecting all internal Eco RI sites in the CMV-C ds-cDNA molecules. After Eco methylation the CMV-C ds-cDNA molecules were treated again with E coli polymorse I (Klenow fragment) to ensure that all ends (5' and 3') were flush, then these molecules were ligated to Eco RI linkers using T4-Ligase. After ligation the CMV-C ds-cDNA molecules were separated from contaminating linker by size fractionation on a GYOG column (1cm X 30cm). The fraction containing the majority of the CMV-C ds-cDNA molecules was EtOH precipitated, followed by resuspension in 10 μg of H20.
About 100 μg of these Eco RI linked CMV-C ds-cDNA molecules were removed and mixed with lμg of λ gT11 arms (commercially available) and ligated together using T4 ligase. The recombinant GT 11-CMV-C were plated using E. coli Up50supF as host and these plates (10-4 clones) were screened for clones containing CMV-C coat protein gene coding region using p-labeled CMV-whiteleaf SS-cDNA as probe. From this screening, a clone, λ GT11-CMV9.9 was isolated. It contained an EcoRI insert of 1400 base pair, enough to encode the complete CMV coat protein. This CMV coat protein gene can be expressed in plant tissues once a plant-active promoter and poly (A) signal are attached to its 5' and 3' regions, respectively. The scheme to accomplish this is shown in Chart 3.
Attachment of the constitutive cauliflower mosaic virus (CaMV) 35S promoter was done by first doing a partial AccI and complete EcoRI digests of clone pCMV9.9 which was obtained by cloning the Eco RI insert from Lambda GT11-CMV9.9 into EcoRI cut puc 19 (commercially available). The 1100 bp CMV-C coat protein gene fragment was removed, both ends were blunted, and this fragment was cloned into the jjmal site of pDH51 (Pietrzak et al. (1986). fiuc. Acids Res. 14:5857) which is available from A.T. Mohn, Friedrick Mieschen Institut, Basel, Switzerland to obtain clone pDH51/cP19.. This positioned the CMV-C coat protein gene downstream of the CaMV 35S promoter and upstream from the CaMV poly (A) signal sequence. To ensure a high level of expression other poly (A) signal sequences (which may function better than the CaMV 35S poly (A) signal) can be attached, such as the poly (A) signal from the seed storage protein gene phaseolin (Slightom et al. (1983) Proc. Natl. Acad. Sci. 80:1897). To facilitate engineering, this plant expressible CMV-C coat protein gene was removed from clone pDH51/CP19 by an EcoRI digest and the 1800 bp fragment was cloned into pUCl813 (which contains more restriction enzyme sites and is available from Dr. R. Kay, Washington State University, Pullman, Washington. The resulting clone, pUCl813/CP19, was then partially digested with Hindlll and the 1800 bp fragment was cloned into the binary vector pGA482 to obtain the new clone, pGA482/CPl9H (see Chart 3). This binary plasmid, or its derivatives, can be transferred into Agrobacterium strains: A208, C58, LBA4404, C58Z707, A4RS, A4RS(pRiB28b) and others. Using the transformation method of this invention, this plant expressible CMV-C
coat protein gene (or any other plant virus coat protein gene) can be transferred into a dicotyledonous plant species such as, cucumber, squash, melon, zucchini, pepper, etc. The development of these new cultivars are useful because of their resistance to infections by specific virus or viruses (if more than one virus coat protein gene construction is transferred to a single plant). Example 5 Transfer of Herbicide Resistance
The purpose of this example is to illustrate how to generate plant expressible genes which allow a plant to be resistant to specific classes of herbicides. Such plants are useful for many reasons; (i) herbicides normally lethal can be used, and (ii) different crops can be used in close rotations on soil which may contain residual amounts of a previously used herbicide that is normally lethal to the second crop. Two genes of interest are mutant derivatives (derived from plant or bacterial sources) of the aceto¬lactate synthase (ALS) gene which are not sensistive to chlorsulfuron and sulfometuron methyl herbicides (Falco et al., (1985) Biotech. Plant Sci. Academic Press, Inc. page 313) and mutants of the gene encoding enolpyruvylshikimate-3-phosphate synthase (EPSPS) (Stalker et al, (1985) J. Biol. Chem., 260:4724) which are not sensitive to the herbicide glyphosate.
A gene which encodes an important enzyme which is either resistant to or detoxifies a specific herbicide is cloned downstream from a plant active promoter, such as: CaMV 35S, ribulose-1,5-bisphosphate carboxylase small subunit gene, or other strong plant gene promoter and upstream from a plant gene poly (A) signal sequence, see Chart 4. This gene is then be cloned into an Agrobacterium-derived vector (either binary or cis) and using the above-described plant transformation method, such a gene is be transferred into many dicotyledonous plant species, such as: soybean, common bean, peppers, melons, etc. Example 6 Transfer of Insect-Resistant Gene
In nature, numerous polypeptides exist which are toxic to insect pests. The best known protein toxins are those associated with different strains of Bacillus thuringiensis: for example, B. israelenis active against Diptera (mosquitoes and blackflies), B. thuringinensis active against Lepidoptera, and B. san diego active against Coleoptera. The toxi protein found in each of these bacteria is highly specific to insect pests; they are not toxic to other
organisms. Thus the transfer and expression of genes encoding such toxic proteins in plants are beneficial in reducing insect damage without using chemical insecticides thereby avoiding risk to other organisms. The genes encoding many of these toxic proteins have been isolated and sequenced (Schnepf et al. (1985) J. Biol. Chem. , 260:6264; Waalwijk et al., (1985) Nucl. Acids Res., 13:8207; Sekar et al (1987) Proc. Natl. Acad. Sci.. 84:7036). The transfer of the B . thuringiensis toxic gene into tobacco and its usefulness in protecting the plant from insect damage has been reported (Vaeck et al. (1987) Nature 328:33). Thus, the combination of using the plant transformation system described here and plant expressible Bacillus toxin gene (see Chart 5) allows for the transfer of a useful trait to any dicotyledonous species for which tissue-culture based transformation systems are inefficient or have not been developed, such as: common bean, soybean, melon, cucumber, squash, zucchini, pepper, etc.
Claims
1. A process for producing a transgenic plant which comprises: (a) germinating a seed of a plant; (b) inoculating the meristematic or mesocotyl cells produced during germination, prior to their differentiation, with a virulent or non-virulent Agrobacterium strain containing a transferable gene in an Agrobacterium derived vector; and
(c) allowing the cells to differentiate into mature plants, with the proviso that the plant cannot be from the family Arabidopsis thaliana.
2. A process according to claim 1 wherein the vector is a plasmid adapted for either transfer in trans- or cis- configuration.
3. A process according to claim 2 wherein the the vector is a binary plasmid adapted for transfer in the trans configuration.
4. A process according to claim 3 wherein the plant is dicotyledonous.
5. A process according to claim 4 wherein one of the cotyledons is removed prior to inoculation.
6. A transgenic plant prepared by the process of claim 1.
7. A transgenic dicotyledonous plant according to claim 6.
8. A plant according to claim 7 wherein the plant is a member of the family leguminoseae.
9. A plant according to claim 8 wherein the plant is a soybean.
10. A plant according to claim 9 wherein the plant is common bean.
11. A plant according to claim 10 wherein the plant gene is the gene for phaseolin.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT8989900780T ATE105585T1 (en) | 1987-12-21 | 1988-12-16 | TRANSFORMATION OF GERMINATED PLANT SEEDS USING AGROBACTERIUM. |
DE3889546T DE3889546T2 (en) | 1987-12-21 | 1988-12-16 | TRANSFORMATION OF Germinating PLANT SEEDS WITH THE HELP OF AGROBACTERIUM. |
EP89900780A EP0397687B1 (en) | 1987-12-21 | 1988-12-16 | Agrobacterium mediated transformation of germinating plant seeds |
DK126690A DK126690A (en) | 1987-12-21 | 1990-05-22 | TRANSGENIC PLANT AND PROCEDURES FOR PRODUCING THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13565587A | 1987-12-21 | 1987-12-21 | |
US135,655 | 1987-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989005859A1 true WO1989005859A1 (en) | 1989-06-29 |
Family
ID=22469055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/004464 WO1989005859A1 (en) | 1987-12-21 | 1988-12-16 | Agrobacterium mediated transformation of germinating plant seeds |
Country Status (9)
Country | Link |
---|---|
US (2) | US5169770A (en) |
EP (1) | EP0397687B1 (en) |
JP (1) | JPH04501201A (en) |
KR (1) | KR0154872B1 (en) |
AT (1) | ATE105585T1 (en) |
AU (2) | AU633248B2 (en) |
DE (1) | DE3889546T2 (en) |
DK (1) | DK126690A (en) |
WO (1) | WO1989005859A1 (en) |
Cited By (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004332A1 (en) * | 1989-09-20 | 1991-04-04 | The Upjohn Company | Somatic embryogenesis of squash |
EP0424047A1 (en) * | 1989-10-17 | 1991-04-24 | Pioneer Hi-Bred International, Inc. | Tissue culture method for transformation of plant cells |
WO1992006205A1 (en) * | 1990-09-27 | 1992-04-16 | Clovis Matton N.V. | A process for the gene manipulation of plant cells, recombinant plasmids, recombinant bacteria, plants |
US5543576A (en) * | 1990-03-23 | 1996-08-06 | Mogen International | Production of enzymes in seeds and their use |
US5593963A (en) * | 1990-09-21 | 1997-01-14 | Mogen International | Expression of phytase in plants |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
US5990281A (en) * | 1996-09-30 | 1999-11-23 | Genentech, Inc. | Vertebrate smoothened proteins |
US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
WO2000037663A2 (en) * | 1998-12-23 | 2000-06-29 | The Samuel Roberts Noble Foundation, Inc. | Plant transformation process |
US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
US6160201A (en) * | 1993-07-09 | 2000-12-12 | Seminis Vegetable Seeds, Inc. | Lettuce infectious yellows virus genes |
US6291643B1 (en) | 1997-06-05 | 2001-09-18 | Board Of Reports, The University Of Texas System | Apaf-1 an activator of caspase-3 |
US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
WO2002030463A2 (en) | 2000-10-12 | 2002-04-18 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
EP1236801A2 (en) * | 2001-02-26 | 2002-09-04 | The Agri-Biotechnology Research Center of Shanxi | Method of agrobacterium mediated plant transformation through treatment of germinating seeds |
US6462176B1 (en) | 1996-09-23 | 2002-10-08 | Genentech, Inc. | Apo-3 polypeptide |
US6469144B1 (en) | 1996-04-01 | 2002-10-22 | Genentech, Inc. | Apo-2LI and Apo-3 polypeptides |
US6555335B1 (en) | 1999-12-30 | 2003-04-29 | Genencor International, Inc. | Xylanase from Trichoderma reesei , method for production thereof, and methods employing this enzyme |
US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
EP1382679A2 (en) | 1995-09-08 | 2004-01-21 | Genentech, Inc. | Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists |
US6727079B1 (en) | 1998-02-25 | 2004-04-27 | The United States Of America As Represented By The Department Of Health And Human Services | cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product |
US6740739B1 (en) | 1998-01-15 | 2004-05-25 | Genentech, Inc. | Substitutional variants of APO-2 ligand |
US6746668B2 (en) | 1996-01-09 | 2004-06-08 | Genentech, Inc. | Apo-2 ligand |
US6764679B2 (en) | 1997-09-18 | 2004-07-20 | Genentech, Inc. | Antibodies to DcR3 Polypeptide, a TNFR Homolog |
US7033627B2 (en) | 1990-03-23 | 2006-04-25 | Syngenta Mogen B.V. | Production of enzymes in seeds and their use |
EP1666052A1 (en) | 2000-02-16 | 2006-06-07 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of TNF-related molecules |
US7164002B2 (en) | 2002-02-06 | 2007-01-16 | Genentech, Inc. | FVIIa antagonists |
US7173115B2 (en) | 2000-01-13 | 2007-02-06 | Genentech, Inc. | Stra6 polypeptides |
EP1757701A1 (en) | 1999-12-24 | 2007-02-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
EP1820859A2 (en) | 1998-12-22 | 2007-08-22 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
EP1865061A2 (en) | 1998-05-15 | 2007-12-12 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
EP1895017A2 (en) | 2002-10-03 | 2008-03-05 | Genentech, Inc. | Use of A33 antigens and JAM-IT |
WO2008033890A2 (en) | 2006-09-12 | 2008-03-20 | Beth Israel Deaconess Medical Center, Inc. | Compositions containing alpha-1-antitrypsin and methods for use |
EP1944317A2 (en) | 2000-09-01 | 2008-07-16 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1953173A1 (en) | 1999-06-15 | 2008-08-06 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids endoding the same |
EP1958965A2 (en) | 1997-08-25 | 2008-08-20 | Genentech, Inc. | Agonist antibodies to a musk receptor, and their therapeutic uses |
EP1967587A1 (en) | 1997-10-10 | 2008-09-10 | Genentech, Inc. | APO-3 Ligand |
EP1992643A2 (en) | 2001-06-20 | 2008-11-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP1995321A2 (en) | 2005-08-15 | 2008-11-26 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
EP2002714A1 (en) | 2005-11-21 | 2008-12-17 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
EP2011886A2 (en) | 2002-04-16 | 2009-01-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2014677A1 (en) | 1997-11-21 | 2009-01-14 | Genentech, Inc. | A-33 related antigens and their pharmacological uses |
EP2014298A2 (en) | 2000-08-24 | 2009-01-14 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
EP2014675A1 (en) | 2003-08-11 | 2009-01-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2014770A2 (en) | 1997-10-29 | 2009-01-14 | Genentech, Inc. | WNT-1 Iinduced secreted polypeptide WISP-2 |
EP2033970A2 (en) | 1997-10-29 | 2009-03-11 | Genentech, Inc. | WNT-1 inducible genes |
EP2042597A1 (en) | 2000-06-23 | 2009-04-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2050335A1 (en) | 2006-02-17 | 2009-04-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
EP2050762A2 (en) | 1998-03-10 | 2009-04-22 | Genentech, Inc. | Novel polypeptides and nucleic acids encoding the same |
EP2065467A2 (en) | 2001-02-22 | 2009-06-03 | Genentech, Inc. | Anti-interferon-alpha antibodies |
EP2067472A1 (en) | 2002-01-02 | 2009-06-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2075253A1 (en) | 2000-06-23 | 2009-07-01 | Genentech, Inc. | Compositions and methds for the diagnosis and treatment of disorders involving angiogensis |
EP2075334A1 (en) | 2000-06-23 | 2009-07-01 | Genentech, Inc. | EG-VEGF nucleic acids and polypeptides and methods of use |
EP2083079A1 (en) | 1997-06-18 | 2009-07-29 | Genentech, Inc. | Apo-2DcR |
EP2082645A1 (en) | 2006-04-19 | 2009-07-29 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
EP2083018A2 (en) | 2003-04-16 | 2009-07-29 | Genentech, Inc. | Compositions and methods relating to STOP-1 |
EP2085096A2 (en) | 2002-09-11 | 2009-08-05 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
EP2116551A1 (en) | 2002-09-11 | 2009-11-11 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2143438A1 (en) | 2001-09-18 | 2010-01-13 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2161283A1 (en) | 2003-11-17 | 2010-03-10 | Genentech, Inc. | Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin |
US7705195B2 (en) | 2002-06-07 | 2010-04-27 | Genentech, Inc. | Screening method |
EP2180054A1 (en) | 1999-12-24 | 2010-04-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
EP2186402A1 (en) | 2005-06-06 | 2010-05-19 | Genentech, Inc. | Knock-out animal models for novel genes and methods of use |
EP2228446A1 (en) | 1999-12-01 | 2010-09-15 | Genentech, Inc. | Secreted and transmembrane polypeptieds and nucleic acids encoding the same |
EP2233149A1 (en) | 2007-10-16 | 2010-09-29 | ZymoGenetics, Inc. | Combination of BLYS inhibition and anti-CD20 agents for treatment of autoimmune disease |
WO2010120561A1 (en) | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
EP2256134A1 (en) | 2003-11-13 | 2010-12-01 | Hanmi Pharmaceutical Co., Ltd. | IgG Fc fragment for a drug carrier and method for the preparation thereof |
EP2258848A1 (en) | 1999-12-23 | 2010-12-08 | Genentech, Inc. | Il-17 homologous polypeptide and therapeutic uses thereof |
EP2272868A2 (en) | 2003-06-05 | 2011-01-12 | Genentech, Inc. | Combination therapy for B cell disorders |
EP2277908A2 (en) | 2003-07-08 | 2011-01-26 | Genentech, Inc. | IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof |
WO2011019619A1 (en) | 2009-08-11 | 2011-02-17 | Genentech, Inc. | Production of proteins in glutamine-free cell culture media |
WO2011031397A1 (en) | 2009-08-06 | 2011-03-17 | Genentech, Inc. | Method to improve virus removal in protein purification |
EP2305823A1 (en) | 2001-01-15 | 2011-04-06 | Wista Laboratories Ltd. | Materials and methods relating to protein aggregation in neurodegenerative disease |
EP2308968A1 (en) | 2002-11-26 | 2011-04-13 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2311960A2 (en) | 2001-08-29 | 2011-04-20 | Genentech, Inc. | Bv8 nucleic acids and polypeptides with mitogenic activity |
EP2311956A1 (en) | 1999-06-28 | 2011-04-20 | Genentech, Inc. | Methods for making APO-2 ligand using divalent metal ions |
WO2011050194A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
EP2319929A1 (en) | 1998-12-23 | 2011-05-11 | Genentech, Inc. | IL-1 related polypeptides |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
EP2322201A2 (en) | 2002-10-29 | 2011-05-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2322165A1 (en) | 2001-11-13 | 2011-05-18 | Genentech, Inc. | Apo2 ligand/TRAIL formulations |
WO2011060246A2 (en) | 2009-11-12 | 2011-05-19 | Genentech, Inc. | A method of promoting dendritic spine density |
WO2011066503A2 (en) | 2009-11-30 | 2011-06-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2333069A2 (en) | 1998-05-15 | 2011-06-15 | Genentech, Inc. | Therapeutic uses of IL-17 homologous polypeptides |
EP2332956A1 (en) | 2002-07-08 | 2011-06-15 | Genentech, Inc. | Antibody binding to PRO71238 |
EP2335725A1 (en) | 2003-04-04 | 2011-06-22 | Genentech, Inc. | High concentration antibody and protein formulations |
EP2348043A1 (en) | 2001-10-02 | 2011-07-27 | Genentech, Inc. | APO-2 ligand variants and uses thereof |
WO2011106297A2 (en) | 2010-02-23 | 2011-09-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2364716A2 (en) | 2002-11-08 | 2011-09-14 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
WO2011139985A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2388265A1 (en) | 2002-02-22 | 2011-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2389951A1 (en) | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
WO2011150110A1 (en) | 2010-05-25 | 2011-12-01 | Genentech, Inc. | Methods of purifying polypeptides |
WO2012036884A2 (en) | 2010-09-15 | 2012-03-22 | Aligna Technologies, Inc. | Bioproduction of aromatic chemicals from lignin-derived compounds |
EP2436781A1 (en) | 2007-02-22 | 2012-04-04 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
EP2444409A2 (en) | 2002-09-16 | 2012-04-25 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2450050A1 (en) | 2006-11-29 | 2012-05-09 | Genentech, Inc. | IL-17A/F heterodimeric polypeptides and therapeutic uses thereof |
US8217223B2 (en) | 2004-06-16 | 2012-07-10 | Basf Plant Science Gmbh | Nucleic acid molecules encoding WRINKLED1-like polypeptides and methods of use in plants |
EP2474557A2 (en) | 2007-07-16 | 2012-07-11 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
EP2500438A2 (en) | 2002-09-25 | 2012-09-19 | Genentech, Inc. | Novel compositions and methods for the treatment of psoriasis |
EP2500032A1 (en) | 2002-06-24 | 2012-09-19 | Genentech, Inc. | APO-2 ligand/trail variants and uses thereof |
WO2012151317A1 (en) | 2011-05-03 | 2012-11-08 | Genentech, Inc. | Vascular disruption agents and uses thereof |
EP2526960A1 (en) | 2003-03-12 | 2012-11-28 | Genentech, Inc. | Use of BV8 and/or EG-VEGF to promote hematopoiesis |
EP2614839A2 (en) | 2006-04-05 | 2013-07-17 | Genentech, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
US8535912B2 (en) | 2009-10-15 | 2013-09-17 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
EP2641618A2 (en) | 2007-07-16 | 2013-09-25 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
EP2657253A2 (en) | 2008-01-31 | 2013-10-30 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
WO2013163606A1 (en) | 2012-04-27 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vascular endothelial growth factor antagonists and methods for their use |
WO2014088934A1 (en) | 2012-12-07 | 2014-06-12 | Danisco Us Inc. | Compositions and methods of use |
WO2014088940A1 (en) | 2012-12-07 | 2014-06-12 | Danisco Us Inc. | Compositions and methods of use |
WO2014145016A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
WO2014144911A2 (en) | 2013-03-15 | 2014-09-18 | Capon Daniel J | Hybrid immunoglobulin containing non-peptidyl linkage |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
US9278131B2 (en) | 2012-08-10 | 2016-03-08 | Adocia | Process for lowering the viscosity of highly concentrated protein solutions |
EP3002295A1 (en) | 2008-04-28 | 2016-04-06 | Genentech, Inc. | Humanized anti-factor d antibodies and uses thereof |
WO2016054194A1 (en) | 2014-09-30 | 2016-04-07 | 1/1Danisco Us Inc | Compositions comprising beta-mannanase and methods of use |
WO2016054168A1 (en) | 2014-09-30 | 2016-04-07 | Danisco Us Inc | Compositions comprising beta mannanase and methods of use |
WO2016054205A1 (en) | 2014-09-30 | 2016-04-07 | Danisco Us Inc | Compositions comprising beta mannanase and methods of use |
WO2016054185A1 (en) | 2014-09-30 | 2016-04-07 | Danisco Us Inc | Compositions comprising beta-mannanase and methods of use |
WO2016054176A1 (en) | 2014-09-30 | 2016-04-07 | Danisco Us Inc | Compositions comprising beta-mannanase and methods of use |
EP3026123A1 (en) | 2006-04-27 | 2016-06-01 | Klaritos, Inc. | Method and kit for predicting antibody therapy |
WO2016100825A1 (en) | 2014-12-18 | 2016-06-23 | Danisco Us Inc | Engineered multifunctional enzymes and methods of use |
WO2016100837A1 (en) | 2014-12-18 | 2016-06-23 | Danisco Us Inc | Engineered multifunctional enzymes and methods of use |
EP3112468A1 (en) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
EP3208612A1 (en) | 2008-04-09 | 2017-08-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP3284825A1 (en) | 2006-11-02 | 2018-02-21 | Daniel J. Capon | Methods of producing hybrid polypeptides with moving parts |
EP3332798A1 (en) | 2010-08-31 | 2018-06-13 | Generon (Shanghai) Corporation Ltd. | Use of interleukin-22 in treating viral hepatitis |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
WO2018200742A1 (en) | 2017-04-25 | 2018-11-01 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
WO2019018629A1 (en) | 2017-07-19 | 2019-01-24 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection |
WO2019148020A1 (en) | 2018-01-26 | 2019-08-01 | Genentech, Inc. | Compositions and methods of use |
WO2019148026A1 (en) | 2018-01-26 | 2019-08-01 | Genentech, Inc. | Il-22 fc fusion proteins and methods of use |
WO2019165140A1 (en) | 2018-02-21 | 2019-08-29 | Genentech, Inc. | DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS |
WO2019213416A1 (en) | 2018-05-02 | 2019-11-07 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection |
US10543169B2 (en) | 2013-11-07 | 2020-01-28 | Generon (Shanghai) Corporation Ltd. | Use of IL-22 dimer in manufacture of a medicament for intravenous administration |
EP3701971A1 (en) | 2014-03-14 | 2020-09-02 | Daniel J. Capon | Compounds useful in preparing hybrid immunoglobulin containing non-peptidyl linkage |
US10786551B2 (en) | 2007-08-06 | 2020-09-29 | Generon (Shanghai) Corporation Ltd. | Use of interleukin-22 in the treatment of fatty liver disease |
WO2020264300A1 (en) | 2019-06-28 | 2020-12-30 | Genentech, Inc. | Composition and methods for stabilizing liquid protein formulations |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
US11339221B2 (en) | 2017-11-01 | 2022-05-24 | Tufts Medical Center, Inc. | Bispecific antibody constructs and methods of use |
US11510966B2 (en) | 2016-04-15 | 2022-11-29 | Evive Biotechnology (Shanghai) Ltd | Use of IL-22 in treating necrotizing enterocolitis |
WO2023168426A1 (en) | 2022-03-03 | 2023-09-07 | Enosi Therapeutics Corporation | Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5244802A (en) | 1987-11-18 | 1993-09-14 | Phytogen | Regeneration of cotton |
US6753463B1 (en) | 1987-11-18 | 2004-06-22 | Mycogen Corporation | Transformed cotton plants |
ATE105585T1 (en) * | 1987-12-21 | 1994-05-15 | Univ Toledo | TRANSFORMATION OF GERMINATED PLANT SEEDS USING AGROBACTERIUM. |
PT89915B (en) * | 1988-03-08 | 1994-10-31 | Ciba Geigy Ag | PROCESS FOR THE PREPARATION OF CHEMICALLY ADJUSTABLE DNA SEQUENCES |
HU219140B (en) * | 1992-11-30 | 2001-02-28 | Zeneca Ltd. | Dna fragments coding oxalate decarboxylase, recombinant molecules containing them, and transformed plant cells containing the recombinant molecules |
US6407313B1 (en) | 1995-08-15 | 2002-06-18 | The Regents Of The University Of California | Regulation of plant development and physiology through plasmodesmatal macromolecular transport of proteins and oligonucleotides |
DE19605279A1 (en) * | 1996-02-13 | 1997-08-14 | Hoechst Ag | Target cell-specific vectors for the introduction of genes into cells, drugs containing such vectors and their use |
US6093695A (en) | 1996-09-26 | 2000-07-25 | Monsanto Company | Bacillus thuringiensis CryET29 compositions toxic to coleopteran insects and ctenocephalides SPP |
US5894079A (en) * | 1996-11-15 | 1999-04-13 | Proctor; Larry M. | Field bean cultivar named enola |
US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
EP1717322B1 (en) | 1997-01-17 | 2012-07-18 | Codexis Mayflower Holdings, LLC | Evolution of whole cells and organisms by recursive sequence recombination |
US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
IL137410A0 (en) | 1998-02-19 | 2001-07-24 | Cotton Inc | A method for the production of transgenic plants using apical shoot tips |
US6586658B1 (en) | 1998-03-06 | 2003-07-01 | Metabolix, Inc. | Modification of fatty acid metabolism in plants |
WO2000006747A2 (en) * | 1998-07-30 | 2000-02-10 | Metabolix, Inc. | Enzymes for biopolymer production |
CA2359868A1 (en) | 1999-01-14 | 2000-07-20 | Monsanto Company | Soybean transformation method |
WO2001023595A2 (en) * | 1999-09-30 | 2001-04-05 | The University Of Toledo | Reduced gravity transformation process and product |
BR0016367B1 (en) | 1999-12-15 | 2013-09-03 | Method to transform soybean explants tissue | |
US20030157592A1 (en) * | 1999-12-16 | 2003-08-21 | Jens Lerchl | Moss genes from physcomitrella patens encoding proteins involved in the synthesis of tocopherols and carotenoids |
DK1254238T3 (en) | 2000-02-09 | 2009-11-30 | Basf Se | New elongase gene and process for producing polyunsaturated fatty acids |
ATE454456T1 (en) * | 2000-02-11 | 2010-01-15 | Metabolix Inc | INTEIN CONTAINING MULTIGEN EXPRESSION CONSTRUCTS |
US7176026B2 (en) | 2001-11-09 | 2007-02-13 | Basf Plant Science Gmbh | Protein kinase stress-related polypeptides and methods of use in plants |
US6720477B2 (en) | 2000-04-07 | 2004-04-13 | Basf Plant Science Gmbh | Signal transduction stress-related proteins and methods of use in plants |
US20020129455A1 (en) * | 2000-12-19 | 2002-09-19 | Yung-Feng Wei | Structure for CD/VCD cleaner |
CA2441265A1 (en) | 2001-03-16 | 2002-09-26 | Basf Plant Science Gmbh | Sugar and lipid metabolism regulators in plants |
GB0107510D0 (en) * | 2001-03-26 | 2001-05-16 | Univ Bristol | New elongase gene and a process for the production of -9-polyunsaturated fatty acids |
EP1392104B1 (en) | 2001-06-04 | 2012-08-15 | BASF Plant Science GmbH | Sugar and lipid metabolism regulators in plants ii |
EP1455568A2 (en) * | 2001-06-15 | 2004-09-15 | The University Of Toledo | Method for transformation of mono- and di- cotyledonous plants using meristematic tissue and nodal callus from dycotiledonous plants |
BRPI0211809B1 (en) | 2001-08-09 | 2019-04-24 | University Of Saskatchewan | METHOD FOR THE CONTROL OF WEED HERBS IN THE NEIGHBORHOODS OF A WHEAT OR TRITICALE PLANT, METHOD FOR MODIFYING THE TOLERANCE OF A WHEAT OR TRITICALE PLANT AND AN IMMEDAZOLINET PRODUCT RESULTING PLANT A HERBICIDE OF IMIDAZOLINONE |
ATE426330T1 (en) | 2001-08-10 | 2009-04-15 | Basf Plant Science Gmbh | SUGAR AND LIPID METABOLISM REGULATORS IN PLANTS III |
US20050044595A1 (en) * | 2001-08-24 | 2005-02-24 | Diana Arias | In planta transformation by embryo imbibition of agrobacterium |
CA2459961A1 (en) | 2001-09-05 | 2003-03-13 | Basf Plant Science Gmbh | Protein phosphatase stress-related polypeptides and methods of use in plants |
US20030046733A1 (en) * | 2001-09-06 | 2003-03-06 | Dias Kalyani Mallika | Transformation of soybeans |
US7220585B2 (en) | 2001-11-09 | 2007-05-22 | Basf Plant Science Gmbh | Transcription factor stress-related polypeptides and methods of use in plants |
AU2003209289A1 (en) | 2002-05-01 | 2003-11-17 | The University Of Georgia Research Foundation, Inc. | Transposable elements in rice and methods of use |
US7579517B2 (en) | 2002-05-08 | 2009-08-25 | Basf Plant Science Gmbh | Methods for increasing oil content in plants |
CA2490154A1 (en) * | 2002-06-22 | 2003-12-31 | Syngenta Participations Ag | Method of transforming soybean |
CA2492167C (en) | 2002-07-10 | 2015-06-16 | The Department Of Agriculture, Western Australia | Wheat plants having increased resistance to imidazolinone herbicides |
EP2272966A3 (en) | 2002-08-02 | 2011-07-06 | BASF Plant Science GmbH | Sugar and lipid metabolism regulators in plants IV |
CA2494626A1 (en) | 2002-08-07 | 2004-03-04 | Basf Plant Science Gmbh | Nucleic acid sequences encoding proteins associated with abiotic stress response |
EP2322633A3 (en) | 2003-02-17 | 2011-08-17 | Metanomics GmbH | Preparation of organisms with faster growth and/or higher yield |
US7537920B2 (en) | 2003-02-27 | 2009-05-26 | Basf Plant Science Gmbh | Method for the production of polyunsaturated fatty acids |
CA2520795C (en) | 2003-03-31 | 2015-06-23 | University Of Bristol | Novel plant acyltransferases specific for long-chained, multiply unsaturated fatty acids |
EP1641930B1 (en) | 2003-04-15 | 2011-06-29 | BASF Plant Science GmbH | Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress |
US9382526B2 (en) | 2003-05-28 | 2016-07-05 | Basf Aktiengesellschaft | Wheat plants having increased tolerance to imidazolinone herbicides |
ES2379553T3 (en) | 2003-08-29 | 2012-04-27 | Instituto Nacional De Tecnologia Agropecuaria | Rice plants that have increased tolerance to imidazolinone herbicides |
AU2004309171B2 (en) | 2003-12-23 | 2010-03-04 | Basf Plant Science Gmbh | Sugar and lipid metabolism regulators in plants VI |
KR101179538B1 (en) * | 2004-01-20 | 2012-09-05 | (주)인비트로플랜트 | A transformation method for viviparous plant |
US20050220901A1 (en) * | 2004-03-22 | 2005-10-06 | Huttenbauer Samuel Jr | Methods of pharmaceutical separation from plants |
MXPA06013357A (en) * | 2004-06-07 | 2007-03-01 | Basf Plant Science Gmbh | Improved transformation of soybean. |
CN104178511A (en) | 2004-07-31 | 2014-12-03 | 梅坦诺米克斯有限公司 | Preparation of organisms with faster growth and/or higher yield |
WO2006013072A2 (en) | 2004-08-02 | 2006-02-09 | Basf Plant Science Gmbh | Method for isolation of transcription termination sequences |
CA2580736A1 (en) | 2004-09-20 | 2006-03-30 | Basf Plant Science Gmbh | Arabidopsis genes encoding proteins involved in sugar and lipid metabolism and methods of use |
CN103289961A (en) | 2004-09-24 | 2013-09-11 | 巴斯福植物科学有限公司 | Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress |
CA2579927A1 (en) | 2004-09-24 | 2006-03-30 | Basf Plant Science Gmbh | Plant cells and plants with increased tolerance to environmental stress |
EP2166100B1 (en) | 2005-03-08 | 2012-07-18 | BASF Plant Science GmbH | Expression enhancing intron sequences |
US7732680B2 (en) | 2005-03-16 | 2010-06-08 | Metabolix, Inc. | Chemically inducible expression of biosynthetic pathways |
CN101203611B (en) | 2005-04-19 | 2013-08-14 | 巴斯福植物科学有限公司 | Improved methods controlling gene expression |
CA2612016A1 (en) | 2005-06-17 | 2006-12-21 | Basf Plant Science Gmbh | Lecitin-like protein kinase stress-related polypeptides and methods of use in plants |
EP2333087A1 (en) | 2005-07-18 | 2011-06-15 | BASF Plant Science GmbH | Yield increase in plants overexpressing the SHSRP genes |
CN101228277B (en) | 2005-07-18 | 2013-11-27 | 巴斯福植物科学有限公司 | Yield increase in plants overexpressing ACCDP genes |
EP1915452A2 (en) | 2005-08-12 | 2008-04-30 | BASF Plant Science GmbH | Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress |
WO2007039454A1 (en) | 2005-09-20 | 2007-04-12 | Basf Plant Science Gmbh | Methods for controlling gene expression using ta-siran |
EP1974024A2 (en) | 2005-12-09 | 2008-10-01 | BASF Plant Science GmbH | Nucleic acid molecules encoding polypeptides involved in regulation of sugar and lipid metabolism and methods of use viii |
US20090172834A1 (en) | 2006-03-24 | 2009-07-02 | Basf Plant Science Gmbh | Proteins Associated With Abiotic Stress Response And Homologs |
CN101589148B (en) | 2006-10-13 | 2014-07-02 | 巴斯福植物科学有限公司 | Plants with increased yield |
CA2681515A1 (en) | 2007-03-23 | 2008-10-02 | Basf Plant Science Gmbh | Transgenic plants with increased stress tolerance and yield expressing a lrp-2 protein |
EP2492345A3 (en) | 2007-05-04 | 2012-12-12 | BASF Plant Science GmbH | Seed enhancement by combinations of pyruvate kinases |
DE112008001452T5 (en) | 2007-05-22 | 2010-12-16 | Basf Plant Science Gmbh | Plants with increased tolerance and / or resistance to environmental stress and increased biomass production |
AU2008257531A1 (en) | 2007-05-29 | 2008-12-04 | Basf Plant Science Gmbh | Transgenic plants with increased stress tolerance and yield |
EP2505653A3 (en) | 2007-07-13 | 2013-05-01 | BASF Plant Science GmbH | Transgenic plants with increased stress tolerance and yield |
CA2694142A1 (en) | 2007-08-02 | 2009-02-05 | Basf Plant Science Gmbh | Transgenic plants with increased stress tolerance and yield |
MX2010002931A (en) | 2007-09-18 | 2010-06-01 | Basf Plant Science Gmbh | Plants with increased yield. |
DE112008002456T5 (en) | 2007-09-21 | 2011-01-13 | Basf Plant Science Gmbh | Plants with increased yield |
WO2009068588A2 (en) | 2007-11-27 | 2009-06-04 | Basf Plant Science Gmbh | Transgenic plants with increased stress tolerance and yield |
CA2709640A1 (en) | 2007-12-17 | 2009-06-25 | Basf Plant Science Gmbh | Lipid metabolism proteins, combinations of lipid metabolism proteins and uses thereof |
US20110041215A1 (en) * | 2007-12-17 | 2011-02-17 | Basf Plant Science Gmbh | Lipid Metabolism Protein And Uses Thereof I (BZIP Transcription Factor) |
BRPI0821748A2 (en) * | 2007-12-19 | 2019-09-24 | Basf Plant Science Gmbh | method for producing a plant with increased yield, isolated nucleic acid molecule, nucleic acid construction, vector, process for producing a polypeptide, polypeptide, antibody, plant cell nucleus, plant cell, plant tissue, propagation material, seed, pollen, progeny, or a plant part, or a high yielding plant, process for the identification of a compound, method for producing an agricultural composition, composition, polypeptide or nucleic acid molecule, use of nucleic acids, and method for the identification of a plant with increased yield |
MX2010009010A (en) * | 2008-02-27 | 2010-09-09 | Basf Plant Science Gmbh | Plants with increased yield. |
CN103923892A (en) | 2008-08-19 | 2014-07-16 | 巴斯夫植物科学有限公司 | Plants with increased yield by increasing or generating one or more activities in a plant or a part thereof |
CN102186979A (en) | 2008-08-20 | 2011-09-14 | 巴斯夫植物科学有限公司 | Transgenic plants comprising as transgene a phosphatidate cytidylyltransferase |
US20110195843A1 (en) | 2008-09-23 | 2011-08-11 | Basf Plant Science Gmbh | Plants with Increased Yield (LT) |
WO2010034652A1 (en) | 2008-09-23 | 2010-04-01 | Basf Plant Science Gmbh | Transgenic plants with increased yield |
EP2350289A1 (en) | 2008-10-23 | 2011-08-03 | BASF Plant Science GmbH | Plants with increased yield (nue) |
AU2009306369A1 (en) | 2008-10-23 | 2010-04-29 | Basf Plant Science Gmbh | A method for producing a transgenic cell with increased gamma-aminobutyric acid (GABA) content |
MX2011007920A (en) | 2009-01-28 | 2011-09-06 | Basf Plant Science Co Gmbh | Transgenic plants having altered nitrogen metabolism. |
CN102300992A (en) | 2009-01-28 | 2011-12-28 | 巴斯夫植物科学有限公司 | Engineering NF-YB transcription factors for enhanced drought resistance and increased yield in transgenic plants |
AU2010221135A1 (en) | 2009-03-05 | 2011-09-29 | Metabolix, Inc. | Propagation of transgenic plants |
WO2010102293A1 (en) | 2009-03-06 | 2010-09-10 | Metabolix, Inc. | Method of positive plant selection using sorbitol dehydrogenase |
CA2754916A1 (en) | 2009-03-23 | 2010-09-30 | Basf Plant Science Company Gmbh | Transgenic plants with altered redox mechanisms and increased yield |
AU2010275363A1 (en) | 2009-07-23 | 2012-02-02 | Basf Plant Science Company Gmbh | Plants with increased yield |
EP2501816A4 (en) | 2009-11-17 | 2013-07-03 | Basf Plant Science Co Gmbh | Plants with increased yield |
CN102971428A (en) | 2010-05-04 | 2013-03-13 | 巴斯夫欧洲公司 | Plants having increased tolerance to herbicides |
US8232454B2 (en) * | 2010-05-20 | 2012-07-31 | Shyi-Dong Yeh | Gene-transfer vector comprising helper-component protease gene of papaya ringspot virus for broad-spectrum virus resistance in crops and use thereof |
UA121371C2 (en) | 2010-12-16 | 2020-05-25 | Басф Агро Б. В. | Plants having increased tolerance to herbicides |
CA2867139A1 (en) | 2011-04-11 | 2012-10-18 | Targeted Growth, Inc. | Identification and the use of krp mutants in plants |
WO2013006861A1 (en) | 2011-07-07 | 2013-01-10 | University Of Georgia Research Foundation, Inc. | Sorghum grain shattering gene and uses thereof in altering seed dispersal |
WO2013024121A2 (en) | 2011-08-18 | 2013-02-21 | Basf Plant Science Company Gmbh | Increase of sucrose transporter activity in the seeds of plants |
WO2013184768A1 (en) | 2012-06-05 | 2013-12-12 | University Of Georgia Research Foundation, Inc. | Compositions and methods of gene silencing in plants |
AR091489A1 (en) | 2012-06-19 | 2015-02-11 | Basf Se | PLANTS THAT HAVE A GREATER TOLERANCE TO HERBICIDES INHIBITORS OF PROTOPORFIRINOGENO OXIDASA (PPO) |
US10041087B2 (en) | 2012-06-19 | 2018-08-07 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
CA2881787A1 (en) | 2012-08-13 | 2014-02-20 | University Of Georgia Research Foundation, Inc. | Compositions and methods for increasing pest resistance in plants |
BR112015012645A2 (en) | 2012-12-18 | 2018-10-23 | Basf Se | methods for nucleic acid production, molecule and construct, vector, polypeptide, plant cell nucleus, transgenic plant, process, composition, use of nucleic acid and method for controlling weeds |
BR112016002851B1 (en) | 2013-08-12 | 2022-02-22 | BASF Agro B.V. | Nucleic acid molecule, nucleic acid construct, vector, ppo polypeptide, method for controlling unwanted vegetation and use of nucleic acid |
UA123757C2 (en) | 2013-08-12 | 2021-06-02 | Басф Агро Б. В. | Plants having increased tolerance to herbicides |
EP3062606B1 (en) | 2013-10-29 | 2019-03-20 | Biotech Institute, LLC | Breeding, production, processing and use of specialty cannabis |
WO2015150465A2 (en) | 2014-04-03 | 2015-10-08 | Basf Se | Plants having increased tolerance to herbicides |
MX2017009541A (en) | 2015-01-21 | 2018-05-07 | Basf Se | Plants having increased tolerance to herbicides. |
BR112017016789A2 (en) | 2015-02-11 | 2018-05-08 | Basf Se | methods for producing a transgenic plant, for controlling unwanted vegetation and for plant cultivation, nucleic acid molecule, nucleic acid construction, vector, mutated hppd polypeptide, plant cell nucleus, transgenic plant cell nucleus, transgenic plant, use of nucleic acid, useful combination, process for preparing a useful combination and use of a useful combination |
MA45030A (en) | 2016-05-20 | 2019-03-27 | Basf Agro Bv | DOUBLE TRANSIT PEPTIDES FOR TARGETING POLYPEPTIDES |
AU2017294685B2 (en) | 2016-07-15 | 2023-10-26 | Basf Se | Plants having increased tolerance to herbicides |
CN109790153A (en) | 2016-07-27 | 2019-05-21 | 巴斯夫农业公司 | Plant with increased herbicide tolerant |
EP3559243A1 (en) | 2016-12-20 | 2019-10-30 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
WO2019106568A1 (en) | 2017-11-29 | 2019-06-06 | Basf Se | Plants having increased tolerance to herbicides |
EA202091721A1 (en) | 2018-01-17 | 2020-11-27 | Басф Се | PLANTS WITH INCREASED HERBICIDE RESISTANCE |
CN108642079A (en) * | 2018-06-11 | 2018-10-12 | 吉林省农业科学院 | A kind of corn genetic transformation method of non-tissue cultures |
CN115605082A (en) * | 2019-11-26 | 2023-01-13 | 先正达农作物保护股份公司(Ch) | Transformation method |
WO2022093977A1 (en) | 2020-10-30 | 2022-05-05 | Fortiphyte, Inc. | Pathogen resistance in plants |
AU2022340861A1 (en) | 2021-09-03 | 2024-03-14 | BASF Agricultural Solutions Seed US LLC | Plants having increased tolerance to herbicides |
WO2024052856A1 (en) | 2022-09-09 | 2024-03-14 | Friedrich Alexander Universität Erlangen-Nürnberg | Plant regulatory elements and uses thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0064720A2 (en) * | 1981-05-04 | 1982-11-17 | The Research And Development Institute Inc. At Montana State University | Compositions containing and methods of use of an infectivity-cured Hr plasmid-bearing microorganism |
FR2560744A1 (en) * | 1983-10-26 | 1985-09-13 | Phytogen Prod Inc | Method for the genetic transformation of dicotyledonous plant seeds in order to favour the growth of seminal roots, and seeds thus obtained. |
EP0241963A1 (en) * | 1986-03-26 | 1987-10-21 | "Centre d'Etude de l'Energie Nucléaire", "C.E.N." | Process for treating plant material to obtain the expression of at least one gene, and plant material in which that gene is expressed |
EP0256751A2 (en) * | 1986-08-04 | 1988-02-24 | Lubrizol Genetics Inc. | Transformation, somatic embryogenesis and whole plant regeneration method for glycine species |
EP0267159A2 (en) * | 1986-11-07 | 1988-05-11 | Ciba-Geigy Ag | Process for the genetic modification of monocotyledonous plants |
EP0301749A2 (en) * | 1987-07-29 | 1989-02-01 | Agracetus, Inc. | Particle-mediated transformation of soybean plants and lines |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE105585T1 (en) * | 1987-12-21 | 1994-05-15 | Univ Toledo | TRANSFORMATION OF GERMINATED PLANT SEEDS USING AGROBACTERIUM. |
-
1988
- 1988-12-16 AT AT8989900780T patent/ATE105585T1/en not_active IP Right Cessation
- 1988-12-16 DE DE3889546T patent/DE3889546T2/en not_active Expired - Fee Related
- 1988-12-16 JP JP1500652A patent/JPH04501201A/en active Pending
- 1988-12-16 EP EP89900780A patent/EP0397687B1/en not_active Expired - Lifetime
- 1988-12-16 WO PCT/US1988/004464 patent/WO1989005859A1/en active IP Right Grant
- 1988-12-16 AU AU28187/89A patent/AU633248B2/en not_active Ceased
- 1988-12-16 KR KR1019890701560A patent/KR0154872B1/en not_active IP Right Cessation
- 1988-12-16 US US07/499,515 patent/US5169770A/en not_active Expired - Fee Related
-
1990
- 1990-05-22 DK DK126690A patent/DK126690A/en not_active Application Discontinuation
-
1992
- 1992-12-07 US US07/986,582 patent/US5376543A/en not_active Expired - Fee Related
-
1993
- 1993-04-27 AU AU37152/93A patent/AU648951B2/en not_active Ceased
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0064720A2 (en) * | 1981-05-04 | 1982-11-17 | The Research And Development Institute Inc. At Montana State University | Compositions containing and methods of use of an infectivity-cured Hr plasmid-bearing microorganism |
FR2560744A1 (en) * | 1983-10-26 | 1985-09-13 | Phytogen Prod Inc | Method for the genetic transformation of dicotyledonous plant seeds in order to favour the growth of seminal roots, and seeds thus obtained. |
EP0241963A1 (en) * | 1986-03-26 | 1987-10-21 | "Centre d'Etude de l'Energie Nucléaire", "C.E.N." | Process for treating plant material to obtain the expression of at least one gene, and plant material in which that gene is expressed |
EP0256751A2 (en) * | 1986-08-04 | 1988-02-24 | Lubrizol Genetics Inc. | Transformation, somatic embryogenesis and whole plant regeneration method for glycine species |
EP0267159A2 (en) * | 1986-11-07 | 1988-05-11 | Ciba-Geigy Ag | Process for the genetic modification of monocotyledonous plants |
EP0301749A2 (en) * | 1987-07-29 | 1989-02-01 | Agracetus, Inc. | Particle-mediated transformation of soybean plants and lines |
Non-Patent Citations (8)
Title |
---|
Biological Abstracts/RRM W. Lin et al.: "Soybean tissue culture and genetic transformation" * |
Biological Abstracts/RRM, no. 89:116856 T.C. Hall et al.: "Transformation of plant cells" * |
Chemical Abstracts. vol. 109, 1988, (Columbus, Ohio, US) see page 193 * |
J. Cell Biochem. Suppl. 11B, S.L. Goldman et al.: "Transformation of Zea mays by Agrobacterium tumefaciens: Evidence for stable genetic alterrations", page 26 * |
Mol.Gen Genet, vol. 208, no. 1/2, June 1987, Spring-Verlag K.A. Feldmann et al.: "Agrobacteriummediated transformation of germinating seeds of Arabidopsis thaliana: A nontissue culture approach", pages 1-9 * |
Nature, vol. 325, no. 7000, 7-14 January 1987, (Neptune, NJ, US) N. Grimsley et al.: "Agrobacteriummediated delivery of infectious maize streak virus into maize plants", pages 177-179 * |
Plant Mol. Biol., vol. 8, no. 3, 1987, M. Nijhoff Publishers, Dordrecht (NL) K. Sukhapinda et al.: "Ri-plasmid as a helper for introducing vector DNA into alfalfa plants", pages 209-216 * |
Plant. Molecular Biology, vol. 7, 1986 M. Nijfhoff Publishers, Dordrecht (NL) A.C.F. Graves et al.: "The transformation of Zea mays seedlings with Agrobacterium tumefaciens" pages 43-50 * |
Cited By (227)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004332A1 (en) * | 1989-09-20 | 1991-04-04 | The Upjohn Company | Somatic embryogenesis of squash |
EP0424047A1 (en) * | 1989-10-17 | 1991-04-24 | Pioneer Hi-Bred International, Inc. | Tissue culture method for transformation of plant cells |
US7033627B2 (en) | 1990-03-23 | 2006-04-25 | Syngenta Mogen B.V. | Production of enzymes in seeds and their use |
US5543576A (en) * | 1990-03-23 | 1996-08-06 | Mogen International | Production of enzymes in seeds and their use |
US5714474A (en) * | 1990-03-23 | 1998-02-03 | Mogen International | Production of enzymes in seeds and their use |
US5593963A (en) * | 1990-09-21 | 1997-01-14 | Mogen International | Expression of phytase in plants |
WO1992006205A1 (en) * | 1990-09-27 | 1992-04-16 | Clovis Matton N.V. | A process for the gene manipulation of plant cells, recombinant plasmids, recombinant bacteria, plants |
US6160201A (en) * | 1993-07-09 | 2000-12-12 | Seminis Vegetable Seeds, Inc. | Lettuce infectious yellows virus genes |
EP1382679A2 (en) | 1995-09-08 | 2004-01-21 | Genentech, Inc. | Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists |
US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
US6746668B2 (en) | 1996-01-09 | 2004-06-08 | Genentech, Inc. | Apo-2 ligand |
US7285533B2 (en) | 1996-01-09 | 2007-10-23 | Genentech, Inc. | Apo-2 ligand |
US6469144B1 (en) | 1996-04-01 | 2002-10-22 | Genentech, Inc. | Apo-2LI and Apo-3 polypeptides |
US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
US6462176B1 (en) | 1996-09-23 | 2002-10-08 | Genentech, Inc. | Apo-3 polypeptide |
US6407216B1 (en) | 1996-09-30 | 2002-06-18 | Genentech, Inc. | Vertebrate smoothened antibodies |
US5990281A (en) * | 1996-09-30 | 1999-11-23 | Genentech, Inc. | Vertebrate smoothened proteins |
US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
US7749755B2 (en) | 1997-05-15 | 2010-07-06 | Genentech, Inc. | Apo-2 receptor polynucleotides |
US7314619B2 (en) | 1997-05-15 | 2008-01-01 | Genentech, Inc. | Inducing apoptosis using anti-Apo-2 antibodies |
US8092799B2 (en) | 1997-05-15 | 2012-01-10 | Genentech, Inc. | Antibodies to Apo-2 receptor polypeptides |
US7595046B2 (en) | 1997-05-15 | 2009-09-29 | Genentech, Inc. | Treatment of cancer using anti-Apo-2 antibodies |
US7750118B2 (en) | 1997-05-15 | 2010-07-06 | Genentech, Inc. | Apo-2 receptor polypeptides |
US7939631B2 (en) | 1997-05-15 | 2011-05-10 | Genentech, Inc. | APO-2 receptor polypeptides |
US7807153B2 (en) | 1997-05-15 | 2010-10-05 | Genentech, Inc. | Apo-2 receptor agonist antibodies |
US6291643B1 (en) | 1997-06-05 | 2001-09-18 | Board Of Reports, The University Of Texas System | Apaf-1 an activator of caspase-3 |
EP2083079A1 (en) | 1997-06-18 | 2009-07-29 | Genentech, Inc. | Apo-2DcR |
EP1958965A2 (en) | 1997-08-25 | 2008-08-20 | Genentech, Inc. | Agonist antibodies to a musk receptor, and their therapeutic uses |
US6764679B2 (en) | 1997-09-18 | 2004-07-20 | Genentech, Inc. | Antibodies to DcR3 Polypeptide, a TNFR Homolog |
EP1967587A1 (en) | 1997-10-10 | 2008-09-10 | Genentech, Inc. | APO-3 Ligand |
EP2033970A2 (en) | 1997-10-29 | 2009-03-11 | Genentech, Inc. | WNT-1 inducible genes |
EP2014770A2 (en) | 1997-10-29 | 2009-01-14 | Genentech, Inc. | WNT-1 Iinduced secreted polypeptide WISP-2 |
EP2014677A1 (en) | 1997-11-21 | 2009-01-14 | Genentech, Inc. | A-33 related antigens and their pharmacological uses |
EP2017341A2 (en) | 1998-01-15 | 2009-01-21 | Genentech, Inc. | Apo-2 ligand |
US6740739B1 (en) | 1998-01-15 | 2004-05-25 | Genentech, Inc. | Substitutional variants of APO-2 ligand |
US7342099B2 (en) | 1998-02-25 | 2008-03-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | cDNA encoding a gene BOG (B5T over-expressed gene) and its protein product |
US6727079B1 (en) | 1998-02-25 | 2004-04-27 | The United States Of America As Represented By The Department Of Health And Human Services | cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product |
EP2050762A2 (en) | 1998-03-10 | 2009-04-22 | Genentech, Inc. | Novel polypeptides and nucleic acids encoding the same |
EP1865061A2 (en) | 1998-05-15 | 2007-12-12 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
EP2333069A2 (en) | 1998-05-15 | 2011-06-15 | Genentech, Inc. | Therapeutic uses of IL-17 homologous polypeptides |
EP3112468A1 (en) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
EP2075335A2 (en) | 1998-12-22 | 2009-07-01 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
EP1820859A2 (en) | 1998-12-22 | 2007-08-22 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
EP2330198A1 (en) | 1998-12-23 | 2011-06-08 | Genentech, Inc. | IL-1 related polypeptides |
EP2319929A1 (en) | 1998-12-23 | 2011-05-11 | Genentech, Inc. | IL-1 related polypeptides |
WO2000037663A3 (en) * | 1998-12-23 | 2000-11-09 | Samuel Roberts Noble Found Inc | Plant transformation process |
WO2000037663A2 (en) * | 1998-12-23 | 2000-06-29 | The Samuel Roberts Noble Foundation, Inc. | Plant transformation process |
EP1953173A1 (en) | 1999-06-15 | 2008-08-06 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids endoding the same |
EP1956030A1 (en) | 1999-06-15 | 2008-08-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids endoding the same |
EP2311956A1 (en) | 1999-06-28 | 2011-04-20 | Genentech, Inc. | Methods for making APO-2 ligand using divalent metal ions |
EP2339003A2 (en) | 1999-06-28 | 2011-06-29 | Genentech, Inc. | APO-2 ligand substitutional variants |
EP2228446A1 (en) | 1999-12-01 | 2010-09-15 | Genentech, Inc. | Secreted and transmembrane polypeptieds and nucleic acids encoding the same |
EP2258848A1 (en) | 1999-12-23 | 2010-12-08 | Genentech, Inc. | Il-17 homologous polypeptide and therapeutic uses thereof |
EP2290081A2 (en) | 1999-12-23 | 2011-03-02 | Genentech, Inc. | IL-17 homologous polypeptide and therapeutic uses thereof |
EP2180054A1 (en) | 1999-12-24 | 2010-04-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
EP1757701A1 (en) | 1999-12-24 | 2007-02-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
EP1757311A2 (en) | 1999-12-24 | 2007-02-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US6555335B1 (en) | 1999-12-30 | 2003-04-29 | Genencor International, Inc. | Xylanase from Trichoderma reesei , method for production thereof, and methods employing this enzyme |
US6768001B2 (en) | 1999-12-30 | 2004-07-27 | Genencor International, Inc. | Xylanase from trichoderma reesei, method for production thereof, and methods employing this enzyme |
US7741439B2 (en) | 2000-01-13 | 2010-06-22 | Genentech, Inc. | Isolated stra6 polypeptides |
US7939650B2 (en) | 2000-01-13 | 2011-05-10 | Genentech, Inc. | Stra6 polypeptides |
US7173115B2 (en) | 2000-01-13 | 2007-02-06 | Genentech, Inc. | Stra6 polypeptides |
US7855278B2 (en) | 2000-01-13 | 2010-12-21 | Genentech, Inc. | Antibodies to Stra6 polypeptides |
EP1666052A1 (en) | 2000-02-16 | 2006-06-07 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of TNF-related molecules |
EP2042597A1 (en) | 2000-06-23 | 2009-04-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2792747A1 (en) | 2000-06-23 | 2014-10-22 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2075253A1 (en) | 2000-06-23 | 2009-07-01 | Genentech, Inc. | Compositions and methds for the diagnosis and treatment of disorders involving angiogensis |
EP2075334A1 (en) | 2000-06-23 | 2009-07-01 | Genentech, Inc. | EG-VEGF nucleic acids and polypeptides and methods of use |
EP2077276A1 (en) | 2000-06-23 | 2009-07-08 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogensis |
EP2275549A1 (en) | 2000-06-23 | 2011-01-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2168980A1 (en) | 2000-06-23 | 2010-03-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogensis |
EP2014298A2 (en) | 2000-08-24 | 2009-01-14 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
EP1944317A2 (en) | 2000-09-01 | 2008-07-16 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP2116265A2 (en) | 2000-10-12 | 2009-11-11 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
WO2002030463A2 (en) | 2000-10-12 | 2002-04-18 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
EP2305823A1 (en) | 2001-01-15 | 2011-04-06 | Wista Laboratories Ltd. | Materials and methods relating to protein aggregation in neurodegenerative disease |
EP2065467A2 (en) | 2001-02-22 | 2009-06-03 | Genentech, Inc. | Anti-interferon-alpha antibodies |
EP2292301A2 (en) | 2001-02-22 | 2011-03-09 | Genentech, Inc. | Anti-interferon-alpha antibodies |
EP1236801A3 (en) * | 2001-02-26 | 2002-10-02 | The Agri-Biotechnology Research Center of Shanxi | Method of agrobacterium mediated plant transformation through treatment of germinating seeds |
EP1236801A2 (en) * | 2001-02-26 | 2002-09-04 | The Agri-Biotechnology Research Center of Shanxi | Method of agrobacterium mediated plant transformation through treatment of germinating seeds |
EP2000545A1 (en) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2000148A1 (en) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of prostate cancer |
EP1992643A2 (en) | 2001-06-20 | 2008-11-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2000482A1 (en) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2311960A2 (en) | 2001-08-29 | 2011-04-20 | Genentech, Inc. | Bv8 nucleic acids and polypeptides with mitogenic activity |
EP2151244A1 (en) | 2001-09-18 | 2010-02-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2143438A1 (en) | 2001-09-18 | 2010-01-13 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2153843A1 (en) | 2001-09-18 | 2010-02-17 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2348043A1 (en) | 2001-10-02 | 2011-07-27 | Genentech, Inc. | APO-2 ligand variants and uses thereof |
EP2332531A1 (en) | 2001-11-13 | 2011-06-15 | Genentech, Inc. | Apo2 ligand/TRAIL formulations |
EP2322165A1 (en) | 2001-11-13 | 2011-05-18 | Genentech, Inc. | Apo2 ligand/TRAIL formulations |
EP2067472A1 (en) | 2002-01-02 | 2009-06-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7164002B2 (en) | 2002-02-06 | 2007-01-16 | Genentech, Inc. | FVIIa antagonists |
EP2388265A1 (en) | 2002-02-22 | 2011-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2011886A2 (en) | 2002-04-16 | 2009-01-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7705195B2 (en) | 2002-06-07 | 2010-04-27 | Genentech, Inc. | Screening method |
EP2500032A1 (en) | 2002-06-24 | 2012-09-19 | Genentech, Inc. | APO-2 ligand/trail variants and uses thereof |
EP2332956A1 (en) | 2002-07-08 | 2011-06-15 | Genentech, Inc. | Antibody binding to PRO71238 |
EP2085096A2 (en) | 2002-09-11 | 2009-08-05 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
EP2116551A1 (en) | 2002-09-11 | 2009-11-11 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2444409A2 (en) | 2002-09-16 | 2012-04-25 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2500438A2 (en) | 2002-09-25 | 2012-09-19 | Genentech, Inc. | Novel compositions and methods for the treatment of psoriasis |
EP2434022A2 (en) | 2002-10-03 | 2012-03-28 | Genentech, Inc. | Use of A33 antigens and JAM-IT |
EP1895017A2 (en) | 2002-10-03 | 2008-03-05 | Genentech, Inc. | Use of A33 antigens and JAM-IT |
EP2322202A2 (en) | 2002-10-29 | 2011-05-18 | Genentech, Inc. | Compositions and methods for the treatment of immune diseases |
EP2322201A2 (en) | 2002-10-29 | 2011-05-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2322200A2 (en) | 2002-10-29 | 2011-05-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2322203A2 (en) | 2002-10-29 | 2011-05-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2364716A2 (en) | 2002-11-08 | 2011-09-14 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
EP2311870A1 (en) | 2002-11-26 | 2011-04-20 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2311868A1 (en) | 2002-11-26 | 2011-04-20 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2308968A1 (en) | 2002-11-26 | 2011-04-13 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2314676A1 (en) | 2002-11-26 | 2011-04-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2526960A1 (en) | 2003-03-12 | 2012-11-28 | Genentech, Inc. | Use of BV8 and/or EG-VEGF to promote hematopoiesis |
EP3178492A1 (en) | 2003-04-04 | 2017-06-14 | Genentech, Inc. | High concentration antibody and protein formulations |
EP2335725A1 (en) | 2003-04-04 | 2011-06-22 | Genentech, Inc. | High concentration antibody and protein formulations |
EP2083018A2 (en) | 2003-04-16 | 2009-07-29 | Genentech, Inc. | Compositions and methods relating to STOP-1 |
EP2272868A2 (en) | 2003-06-05 | 2011-01-12 | Genentech, Inc. | Combination therapy for B cell disorders |
EP2277908A2 (en) | 2003-07-08 | 2011-01-26 | Genentech, Inc. | IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof |
EP2784084A1 (en) | 2003-07-08 | 2014-10-01 | Genentech, Inc. | IL-17 A/F heterologous polypeptides and therapeutics uses thereof |
EP3594228A1 (en) | 2003-07-08 | 2020-01-15 | Genentech, Inc. | Il-17a/f heterologous polypedtides and therapeutic uses thereof |
EP2014675A1 (en) | 2003-08-11 | 2009-01-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2256134A1 (en) | 2003-11-13 | 2010-12-01 | Hanmi Pharmaceutical Co., Ltd. | IgG Fc fragment for a drug carrier and method for the preparation thereof |
EP2161283A1 (en) | 2003-11-17 | 2010-03-10 | Genentech, Inc. | Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin |
EP2295073A1 (en) | 2003-11-17 | 2011-03-16 | Genentech, Inc. | Antibody against CD22 for the treatment of tumour of hematopoietic origin |
EP2301568A1 (en) | 2003-11-17 | 2011-03-30 | Genentech, Inc. | Antibody against IRTA2 for the treatment of tumour of hematopoietic origin |
US8217223B2 (en) | 2004-06-16 | 2012-07-10 | Basf Plant Science Gmbh | Nucleic acid molecules encoding WRINKLED1-like polypeptides and methods of use in plants |
EP2186402A1 (en) | 2005-06-06 | 2010-05-19 | Genentech, Inc. | Knock-out animal models for novel genes and methods of use |
EP1995321A2 (en) | 2005-08-15 | 2008-11-26 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
EP2002714A1 (en) | 2005-11-21 | 2008-12-17 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
EP2050335A1 (en) | 2006-02-17 | 2009-04-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
EP2389946A1 (en) | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
EP2389951A1 (en) | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
EP2389948A1 (en) | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
EP2389949A1 (en) | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
EP2389947A1 (en) | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
EP2389950A1 (en) | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
EP2614839A2 (en) | 2006-04-05 | 2013-07-17 | Genentech, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
EP2082645A1 (en) | 2006-04-19 | 2009-07-29 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
EP3026123A1 (en) | 2006-04-27 | 2016-06-01 | Klaritos, Inc. | Method and kit for predicting antibody therapy |
WO2008033890A2 (en) | 2006-09-12 | 2008-03-20 | Beth Israel Deaconess Medical Center, Inc. | Compositions containing alpha-1-antitrypsin and methods for use |
EP3284825A1 (en) | 2006-11-02 | 2018-02-21 | Daniel J. Capon | Methods of producing hybrid polypeptides with moving parts |
EP2450050A1 (en) | 2006-11-29 | 2012-05-09 | Genentech, Inc. | IL-17A/F heterodimeric polypeptides and therapeutic uses thereof |
EP3181147A1 (en) | 2006-11-29 | 2017-06-21 | Genentech, Inc. | Il-17a/f heterodimeric polypeptides and therapeutic thereof |
EP2436781A1 (en) | 2007-02-22 | 2012-04-04 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
EP2474557A2 (en) | 2007-07-16 | 2012-07-11 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
EP2641618A2 (en) | 2007-07-16 | 2013-09-25 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
EP2502937A2 (en) | 2007-07-16 | 2012-09-26 | Genentech, Inc. | Anti-CD 79b Antibodies And Immunoconjugates And Methods Of Use |
US10786551B2 (en) | 2007-08-06 | 2020-09-29 | Generon (Shanghai) Corporation Ltd. | Use of interleukin-22 in the treatment of fatty liver disease |
EP2233149A1 (en) | 2007-10-16 | 2010-09-29 | ZymoGenetics, Inc. | Combination of BLYS inhibition and anti-CD20 agents for treatment of autoimmune disease |
EP2657253A2 (en) | 2008-01-31 | 2013-10-30 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
EP3208612A1 (en) | 2008-04-09 | 2017-08-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP3605088A1 (en) | 2008-04-09 | 2020-02-05 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP3002295A1 (en) | 2008-04-28 | 2016-04-06 | Genentech, Inc. | Humanized anti-factor d antibodies and uses thereof |
WO2010120561A1 (en) | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
EP3309168A1 (en) | 2009-08-06 | 2018-04-18 | F. Hoffmann-La Roche AG | Method to improve virus removal in protein purification |
US10662237B2 (en) | 2009-08-06 | 2020-05-26 | Genentech, Inc. | Method to improve virus filtration capacity |
WO2011031397A1 (en) | 2009-08-06 | 2011-03-17 | Genentech, Inc. | Method to improve virus removal in protein purification |
US11225513B2 (en) | 2009-08-06 | 2022-01-18 | Genentech, Inc. | Method to improve virus filtration capacity |
US8512983B2 (en) | 2009-08-11 | 2013-08-20 | Martin Gawlitzek | Production of proteins in glutamine-free cell culture media |
US10982003B2 (en) | 2009-08-11 | 2021-04-20 | Genentech, Inc. | Production of proteins in glutamine-free cell culture media |
US9714293B2 (en) | 2009-08-11 | 2017-07-25 | Genentech, Inc. | Production of proteins in glutamine-free cell culture media |
EP3760712A1 (en) | 2009-08-11 | 2021-01-06 | F. Hoffmann-La Roche AG | Production of proteins in glutamine-free cell culture media |
WO2011019619A1 (en) | 2009-08-11 | 2011-02-17 | Genentech, Inc. | Production of proteins in glutamine-free cell culture media |
US8535912B2 (en) | 2009-10-15 | 2013-09-17 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
WO2011050194A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011060246A2 (en) | 2009-11-12 | 2011-05-19 | Genentech, Inc. | A method of promoting dendritic spine density |
WO2011066503A2 (en) | 2009-11-30 | 2011-06-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP3002297A2 (en) | 2009-11-30 | 2016-04-06 | F. Hoffmann-La Roche AG | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211) |
WO2011106297A2 (en) | 2010-02-23 | 2011-09-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2011139985A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2011150110A1 (en) | 2010-05-25 | 2011-12-01 | Genentech, Inc. | Methods of purifying polypeptides |
EP3299380A1 (en) | 2010-05-25 | 2018-03-28 | F. Hoffmann-La Roche AG | Methods of purifying polypeptides |
EP3332798A1 (en) | 2010-08-31 | 2018-06-13 | Generon (Shanghai) Corporation Ltd. | Use of interleukin-22 in treating viral hepatitis |
WO2012036884A2 (en) | 2010-09-15 | 2012-03-22 | Aligna Technologies, Inc. | Bioproduction of aromatic chemicals from lignin-derived compounds |
WO2012151317A1 (en) | 2011-05-03 | 2012-11-08 | Genentech, Inc. | Vascular disruption agents and uses thereof |
WO2013163606A1 (en) | 2012-04-27 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vascular endothelial growth factor antagonists and methods for their use |
US9278131B2 (en) | 2012-08-10 | 2016-03-08 | Adocia | Process for lowering the viscosity of highly concentrated protein solutions |
WO2014088940A1 (en) | 2012-12-07 | 2014-06-12 | Danisco Us Inc. | Compositions and methods of use |
WO2014088934A1 (en) | 2012-12-07 | 2014-06-12 | Danisco Us Inc. | Compositions and methods of use |
US9879245B2 (en) | 2012-12-07 | 2018-01-30 | Danisco Us Inc. | Polypeptides having beta-mannanase activity and methods of use |
US10544198B2 (en) | 2013-03-15 | 2020-01-28 | Genentech, Inc. | Methods of accelerating or improving wound healing using IL-22 FC fusion proteins |
US11136365B2 (en) | 2013-03-15 | 2021-10-05 | Genentech, Inc. | Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteins |
US11332507B2 (en) | 2013-03-15 | 2022-05-17 | Genentech, Inc. | IL-22 Fc fusion proteins |
WO2014145016A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
US11155591B2 (en) | 2013-03-15 | 2021-10-26 | Genentech, Inc. | Methods of treating acute pancreatitis using IL-22 fc fusion proteins |
US10087227B2 (en) | 2013-03-15 | 2018-10-02 | Genentech, Inc. | Nucleic acids encoding IL-22 Fc fusion proteins |
EP3385277A1 (en) | 2013-03-15 | 2018-10-10 | F. Hoffmann-La Roche AG | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
EP4039281A1 (en) | 2013-03-15 | 2022-08-10 | Biomolecular Holdings LLC | Hybrid immunoglobulin containing non-peptidyl linkage |
US10160793B2 (en) | 2013-03-15 | 2018-12-25 | Genentech, Inc. | Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins |
US10584155B2 (en) | 2013-03-15 | 2020-03-10 | Genentech, Inc. | Pharmaceutical compositions of IL-22 Fc fusion proteins |
US9815880B2 (en) | 2013-03-15 | 2017-11-14 | Genentech, Inc. | IL-22 Fc fusion proteins |
US11130791B2 (en) | 2013-03-15 | 2021-09-28 | Genentech, Inc. | Methods for treating metabolic syndrome using IL-22 Fc fusion proteins |
EP3611180A1 (en) | 2013-03-15 | 2020-02-19 | Daniel J. Capon | Hybrid immunoglobulin containing non-peptidyl linkage |
WO2014144911A2 (en) | 2013-03-15 | 2014-09-18 | Capon Daniel J | Hybrid immunoglobulin containing non-peptidyl linkage |
US10543169B2 (en) | 2013-11-07 | 2020-01-28 | Generon (Shanghai) Corporation Ltd. | Use of IL-22 dimer in manufacture of a medicament for intravenous administration |
US11654104B2 (en) | 2013-11-07 | 2023-05-23 | Evive Biotechnology (Shanghai) Ltd | Use of IL-22 dimer in manufacture of a medicament for intravenous administration |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
EP4169944A1 (en) | 2014-03-14 | 2023-04-26 | Biomolecular Holdings LLC | Process for preparing hybrid immunoglobulin containing non-peptidyl linkage |
EP3701971A1 (en) | 2014-03-14 | 2020-09-02 | Daniel J. Capon | Compounds useful in preparing hybrid immunoglobulin containing non-peptidyl linkage |
WO2016054185A1 (en) | 2014-09-30 | 2016-04-07 | Danisco Us Inc | Compositions comprising beta-mannanase and methods of use |
WO2016054168A1 (en) | 2014-09-30 | 2016-04-07 | Danisco Us Inc | Compositions comprising beta mannanase and methods of use |
WO2016054205A1 (en) | 2014-09-30 | 2016-04-07 | Danisco Us Inc | Compositions comprising beta mannanase and methods of use |
WO2016054194A1 (en) | 2014-09-30 | 2016-04-07 | 1/1Danisco Us Inc | Compositions comprising beta-mannanase and methods of use |
WO2016054176A1 (en) | 2014-09-30 | 2016-04-07 | Danisco Us Inc | Compositions comprising beta-mannanase and methods of use |
WO2016100825A1 (en) | 2014-12-18 | 2016-06-23 | Danisco Us Inc | Engineered multifunctional enzymes and methods of use |
WO2016100837A1 (en) | 2014-12-18 | 2016-06-23 | Danisco Us Inc | Engineered multifunctional enzymes and methods of use |
US11510966B2 (en) | 2016-04-15 | 2022-11-29 | Evive Biotechnology (Shanghai) Ltd | Use of IL-22 in treating necrotizing enterocolitis |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
EP4230649A2 (en) | 2017-04-25 | 2023-08-23 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
WO2018200742A1 (en) | 2017-04-25 | 2018-11-01 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
WO2019018629A1 (en) | 2017-07-19 | 2019-01-24 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection |
US11339221B2 (en) | 2017-11-01 | 2022-05-24 | Tufts Medical Center, Inc. | Bispecific antibody constructs and methods of use |
WO2019148020A1 (en) | 2018-01-26 | 2019-08-01 | Genentech, Inc. | Compositions and methods of use |
WO2019148026A1 (en) | 2018-01-26 | 2019-08-01 | Genentech, Inc. | Il-22 fc fusion proteins and methods of use |
WO2019165140A1 (en) | 2018-02-21 | 2019-08-29 | Genentech, Inc. | DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS |
WO2019213416A1 (en) | 2018-05-02 | 2019-11-07 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection |
WO2020264300A1 (en) | 2019-06-28 | 2020-12-30 | Genentech, Inc. | Composition and methods for stabilizing liquid protein formulations |
US11865177B2 (en) | 2019-06-28 | 2024-01-09 | Genentech, Inc. | Composition and methods for stabilizing liquid protein formulations |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
WO2023168426A1 (en) | 2022-03-03 | 2023-09-07 | Enosi Therapeutics Corporation | Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
DK126690D0 (en) | 1990-05-22 |
EP0397687A1 (en) | 1990-11-22 |
ATE105585T1 (en) | 1994-05-15 |
AU648951B2 (en) | 1994-05-05 |
US5169770A (en) | 1992-12-08 |
AU2818789A (en) | 1989-07-19 |
US5376543A (en) | 1994-12-27 |
JPH04501201A (en) | 1992-03-05 |
DK126690A (en) | 1990-05-22 |
KR900700605A (en) | 1990-08-16 |
AU3715293A (en) | 1993-08-05 |
KR0154872B1 (en) | 1998-10-15 |
DE3889546T2 (en) | 1994-09-08 |
EP0397687B1 (en) | 1994-05-11 |
AU633248B2 (en) | 1993-01-28 |
DE3889546D1 (en) | 1994-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5376543A (en) | Agrobacterium mediated transformation of germinating plant seeds | |
JP3665321B2 (en) | Enhanced expression in plants | |
Men et al. | Agrobacterium-mediated genetic transformation of a Dendrobium orchid | |
Elliott et al. | Cis-acting elements for light regulation of pea ferredoxin I gene expression are located within transcribed sequences. | |
Rao et al. | Agrobacterium-mediated Transformation of Sunflower (Helianthus annuusL.): A Simple Protocol | |
EP0459643A2 (en) | A recombinant promoter for gene expression in monocotyledonous plants | |
WO1985004899A1 (en) | Methods and vectors for transformation of plant cells | |
US5073675A (en) | Method of introducing spectinomycin resistance into plants | |
KR100477413B1 (en) | Improved integration of exogenous DNA delivered to eukaryotic cells | |
HUT58758A (en) | New signalsequencies | |
EP0573767B1 (en) | Process for production of exogenous gene or its product in plant cells | |
WO2012065528A1 (en) | Identification and use of plant root-specific expression promoter | |
CA2037677C (en) | Process for production of exogenous gene or its product in plant cells | |
JP2002525033A (en) | Pi-ta gene that confers disease resistance to plants | |
JP5186076B2 (en) | Engineering plant senescence using the myb gene promoter and cytokinin biosynthesis genes | |
EP0592685B1 (en) | Plant resistant to two or more viruses and preparation thereof | |
US7557264B2 (en) | Gossypium hirsutum tissue-specific promoters and their use | |
US6664384B1 (en) | Duplicated cassava vein mosaic virus enhancers and uses thereof | |
EP0223417A1 (en) | TL-based sub-T-DNA plasmids | |
US5959181A (en) | Method of preparation of transgenic plants resistant to viral infections and so obtained plants | |
OĞRAŞ et al. | Expression and inheritance of GUS gene in transgenic tobacco plants | |
NZ207766A (en) | Plant structural gene expression | |
AU769546B2 (en) | Method for obtaining transgenic plants expressing a protein with activity producing hydrogen peroxide by transformation by Agrobacterium rhizogenes | |
JP3098353B2 (en) | Production of foreign genes and their products in plant cells | |
Chen et al. | A manuscript to be submitted to Plant Science |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1989900780 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1989900780 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1989900780 Country of ref document: EP |